Philip Morris International (PM) 10-Q 29 Jul 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Jul. 22, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-33708
Entity Registrant Name	Philip Morris International Inc.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	13-3435103
Entity Address, Address Line One	120 Park Avenue
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(917)
Local Phone Number	663-2000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,550,163,328
Entity Central Index Key	0001413329
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PM
Security Exchange Name	NYSE
2.375% Notes due 2022
Document Information [Line Items]
Title of 12(b) Security	2.375% Notes due 2022
Trading Symbol	PM22B
Security Exchange Name	NYSE
2.500% Notes due 2022
Document Information [Line Items]
Title of 12(b) Security	2.500% Notes due 2022
Trading Symbol	PM22
Security Exchange Name	NYSE
2.500% Notes due 2022
Document Information [Line Items]
Title of 12(b) Security	2.500% Notes due 2022
Trading Symbol	PM22C
Security Exchange Name	NYSE
2.625% Notes due 2023
Document Information [Line Items]
Title of 12(b) Security	2.625% Notes due 2023
Trading Symbol	PM23
Security Exchange Name	NYSE
2.125% Notes due 2023
Document Information [Line Items]
Title of 12(b) Security	2.125% Notes due 2023
Trading Symbol	PM23B
Security Exchange Name	NYSE
3.600% Notes due 2023
Document Information [Line Items]
Title of 12(b) Security	3.600% Notes due 2023
Trading Symbol	PM23A
Security Exchange Name	NYSE
2.875% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	2.875% Notes due 2024
Trading Symbol	PM24
Security Exchange Name	NYSE
2.875% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	2.875% Notes due 2024
Trading Symbol	PM24C
Security Exchange Name	NYSE
0.625% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	0.625% Notes due 2024
Trading Symbol	PM24B
Security Exchange Name	NYSE
3.250% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	3.250% Notes due 2024
Trading Symbol	PM24A
Security Exchange Name	NYSE
2.750% Notes due 2025
Document Information [Line Items]
Title of 12(b) Security	2.750% Notes due 2025
Trading Symbol	PM25
Security Exchange Name	NYSE
3.375% Notes due 2025
Document Information [Line Items]
Title of 12(b) Security	3.375% Notes due 2025
Trading Symbol	PM25A
Security Exchange Name	NYSE
2.750% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	2.750% Notes due 2026
Trading Symbol	PM26A
Security Exchange Name	NYSE
2.875% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	2.875% Notes due 2026
Trading Symbol	PM26
Security Exchange Name	NYSE
0.125% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	0.125% Notes due 2026
Trading Symbol	PM26B
Security Exchange Name	NYSE
3.125% Notes due 2027
Document Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2027
Trading Symbol	PM27
Security Exchange Name	NYSE
3.125% Notes due 2028
Document Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2028
Trading Symbol	PM28
Security Exchange Name	NYSE
2.875% Notes due 2029
Document Information [Line Items]
Title of 12(b) Security	2.875% Notes due 2029
Trading Symbol	PM29
Security Exchange Name	NYSE
3.375% Notes due 2029
Document Information [Line Items]
Title of 12(b) Security	3.375% Notes due 2029
Trading Symbol	PM29A
Security Exchange Name	NYSE
0.800% Notes due 2031
Document Information [Line Items]
Title of 12(b) Security	0.800% Notes due 2031
Trading Symbol	PM31
Security Exchange Name	NYSE
3.125% Notes due 2033
Document Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2033
Trading Symbol	PM33
Security Exchange Name	NYSE
2.000% Notes due 2036
Document Information [Line Items]
Title of 12(b) Security	2.000% Notes due 2036
Trading Symbol	PM36
Security Exchange Name	NYSE
1.875% Notes due 2037
Document Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2037
Trading Symbol	PM37A
Security Exchange Name	NYSE
6.375% Notes due 2038
Document Information [Line Items]
Title of 12(b) Security	6.375% Notes due 2038
Trading Symbol	PM38
Security Exchange Name	NYSE
1.450% Notes due 2039
Document Information [Line Items]
Title of 12(b) Security	1.450% Notes due 2039
Trading Symbol	PM39
Security Exchange Name	NYSE
4.375% Notes due 2041
Document Information [Line Items]
Title of 12(b) Security	4.375% Notes due 2041
Trading Symbol	PM41
Security Exchange Name	NYSE
4.500% Notes due 2042
Document Information [Line Items]
Title of 12(b) Security	4.500% Notes due 2042
Trading Symbol	PM42
Security Exchange Name	NYSE
3.875% Notes due 2042
Document Information [Line Items]
Title of 12(b) Security	3.875% Notes due 2042
Trading Symbol	PM42A
Security Exchange Name	NYSE
4.125% Notes due 2043
Document Information [Line Items]
Title of 12(b) Security	4.125% Notes due 2043
Trading Symbol	PM43
Security Exchange Name	NYSE
4.875% Notes due 2043
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2043
Trading Symbol	PM43A
Security Exchange Name	NYSE
4.250% Notes due 2044
Document Information [Line Items]
Title of 12(b) Security	4.250% Notes due 2044
Trading Symbol	PM44
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues including excise taxes	$ 20,409	$ 20,421	$ 39,750	$ 39,776
Excise taxes on products	12,577	12,827	24,172	24,597
Net revenues (Note 10)	7,832	7,594	15,578	15,179
Cost of sales (Note 3)	2,648	2,353	5,256	4,627
Gross profit	5,184	5,241	10,322	10,552
Marketing, administration and research costs (Notes 3 & 17)	2,092	2,093	3,894	3,942
Amortization of intangibles	36	19	74	37
Operating income	3,056	3,129	6,354	6,573
Interest expense, net	126	161	280	328
Pension and other employee benefit costs (Note 5)	5	27	9	55
Earnings before income taxes	2,925	2,941	6,065	6,190
Provision for income taxes	594	646	1,213	1,343
Equity investments and securities (income)/loss, net	(15)	(3)	41	(46)
Net earnings	2,346	2,298	4,811	4,893
Net earnings attributable to noncontrolling interests	113	126	247	303
Net earnings attributable to PMI	$ 2,233	$ 2,172	$ 4,564	$ 4,590
Per share data (Note 8):
Basic earnings per share (in dollars per share)	$ 1.44	$ 1.39	$ 2.94	$ 2.94
Diluted earnings per share (in dollars per share)	$ 1.43	$ 1.39	$ 2.93	$ 2.93

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 2,346	$ 2,298	$ 4,811	$ 4,893
Change in currency translation adjustments:
Cumulative foreign currency translation losses reflected in accumulated other comprehensive losses	413	4	219	227
Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes	36	20	36	20
Amortization of net losses, prior service costs and net transition costs, net of income taxes	55	81	110	162
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes	191	1	301	77
(Gains) losses transferred to earnings, net of income taxes	(46)	(19)	(55)	2
Other comprehensive earnings (losses), net of income taxes	649	87	611	488
Total comprehensive earnings	2,995	2,385	5,422	5,381
Less comprehensive earnings attributable to:
Noncontrolling interests	45	132	324	275
Comprehensive earnings attributable to PMI	$ 2,950	$ 2,253	$ 5,098	$ 5,106

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Earnings (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Change in foreign currency translation adjustments, unrealized gains (losses), tax	$ (151)	$ 60	$ (182)	$ (25)
Net gains (losses) and prior service costs, tax	36	(5)	36	(5)
Amortization of net losses, prior service costs and net transition costs, tax	(9)	(18)	(22)	(36)
Change in fair value of derivatives accounted for as hedges, gains (losses) recognized, tax	(34)	2	(54)	(12)
Change in fair value of derivatives accounted for as hedges, (gains) losses transferred to earnings, tax	$ 7	$ 0	$ 9	$ 0

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 5,036	$ 4,496
Trade receivables (less allowances of $36 in 2022 and $70 in 2021)	3,822	3,123
Other receivables (less allowances of $34 in 2022 and $36 in 2021)	771	817
Inventories:
Leaf tobacco	1,649	1,642
Other raw materials	1,778	1,652
Finished product	4,124	5,426
Total inventory, net	7,551	8,720
Other current assets	1,196	561
Total current assets	18,376	17,717
Property, plant and equipment, at cost	14,559	14,732
Less: accumulated depreciation	8,594	8,564
Total property, plant and equipment, net	5,965	6,168
Goodwill (Note 6)	6,318	6,680
Other intangible assets, net (Note 6)	2,656	2,818
Equity investments (Note 14)	4,328	4,463
Deferred income taxes	714	895
Other assets (less allowances of $20 in 2022 and $21 in 2021)	2,603	2,549
TOTAL ASSETS	40,960	41,290
LIABILITIES
Short-term borrowings (Note 12)	1,558	225
Current portion of long-term debt (Note 12)	4,149	2,798
Accounts payable	3,279	3,331
Accrued liabilities:
Marketing and selling	739	811
Taxes, except income taxes	5,261	6,324
Employment costs	911	1,146
Dividends payable	1,958	1,958
Other	1,862	1,637
Income taxes	830	1,025
Total current liabilities	20,547	19,255
Long-term debt (Note 12)	22,345	24,783
Deferred income taxes	856	726
Employment costs	2,752	2,968
Income taxes and other liabilities	1,720	1,766
Total liabilities	48,220	49,498
Contingencies (Note 10)
STOCKHOLDERS’ (DEFICIT) EQUITY
Common stock, no par value (2,109,316,331 shares issued in 2022 and 2021)	0	0
Additional paid-in capital	2,165	2,225
Earnings reinvested in the business	33,755	33,082
Accumulated other comprehensive losses	(9,043)	(9,577)
Total stockholders' equity before treasury stock	26,877	25,730
Less: cost of repurchased stock (559,171,010 and 559,146,338 shares in 2022 and 2021, respectively)	35,921	35,836
Total PMI stockholders’ deficit	(9,044)	(10,106)
Noncontrolling interests	1,784	1,898
Total stockholders’ deficit	(7,260)	(8,208)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY	$ 40,960	$ 41,290

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Trade receivables, allowances	$ 36	$ 70
Other receivables, allowances	34	36
Other assets, allowances	$ 20	$ 21
Common stock, issued (in shares)	2,109,316,331	2,109,316,331
Repurchased stock (in shares)	559,171,010	559,146,338

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings		$ 4,811	$ 4,893
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization		540	484
Deferred income tax (benefit) provision		(88)	2
Asset impairment and exit costs, net of cash paid (Note 17)		(47)	(26)
Cash effects of changes, net of the effects from acquired companies:
Receivables, net		(627)	(627)
Inventories		867	767
Accounts payable		174	(16)
Accrued liabilities and other current assets		(869)	(940)
Income taxes		(424)	(459)
Pension plan contributions, net of refunds (Note 5)		63
Pension plan contributions, net of refunds (Note 5)			(197)
Other		242	184
Net cash provided by operating activities		4,642	4,065
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures		(478)	(307)
Acquisitions, net of acquired cash (Note 2)		0	(27)
Equity investments		(20)	0
Net investment hedges and other derivatives (Note 7)		514	147
Other		(71)	59
Net cash used in investing activities		(55)	(128)
Short-term borrowing activity by original maturity:
Net issuances (repayments) - maturities of 90 days or less		565	(108)
Issuances - maturities longer than 90 days		795	0
Repayments - maturities longer than 90 days		(15)	0
Long-term debt repaid		(497)	(1,979)
Repurchases of common stock		(209)	0
Dividends paid		(3,897)	(3,752)
Payments to noncontrolling interests and Other (Note 2)		(542)	(284)
Net cash used in financing activities		(3,800)	(6,123)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(244)	(179)
Cash, cash equivalents and restricted cash:
Increase (Decrease)	[1]	543	(2,365)
Balance at beginning of period	[1]	4,500	7,285
Balance at end of period	[1]	$ 5,043	$ 4,920
[1]The amounts for cash, cash equivalents and restricted cash shown above include restricted cash of $7 million and $5 million as of June 30, 2022 and 2021, respectively, and $4 million and $5 million as of December 31, 2021 and 2020, respectively, which were included in other current assets in the condensed consolidated balance sheets.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Restricted cash	$ 7	$ 4	$ 5	$ 5

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-in Capital	Earnings Reinvested in the Business	Accumulated Other Comprehensive Losses	Cost of Repurchased Stock	Noncontrolling Interests
Beginning balance at Dec. 31, 2020	$ (10,631)	$ 0	$ 2,105	$ 31,638	$ (11,181)	$ (35,129)	$ 1,936
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	4,893			4,590			303
Other comprehensive earnings (losses), net of income taxes	488				516		(28)
Issuance of stock awards	111		38			73
Dividends declared	(3,763)			(3,763)
Payments to noncontrolling interests	(298)						(298)
Ending balance at Jun. 30, 2021	(9,200)	0	2,143	32,465	(10,665)	(35,056)	1,913
Beginning balance at Mar. 31, 2021	(9,574)	0	2,080	32,178	(10,746)	(35,060)	1,974
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	2,298			2,172			126
Other comprehensive earnings (losses), net of income taxes	87				81		6
Issuance of stock awards	67		63			4
Dividends declared	(1,885)			(1,885)
Payments to noncontrolling interests	(193)						(193)
Ending balance at Jun. 30, 2021	(9,200)	0	2,143	32,465	(10,665)	(35,056)	1,913
Beginning balance at Dec. 31, 2021	(8,208)	0	2,225	33,082	(9,577)	(35,836)	1,898
Ending balance at Mar. 31, 2022	(8,203)	0	2,118	33,468	(9,760)	(35,924)	1,895
Beginning balance at Dec. 31, 2021	(8,208)	0	2,225	33,082	(9,577)	(35,836)	1,898
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	4,811			4,564			247
Other comprehensive earnings (losses), net of income taxes	611				705		(94)
Issuance of stock awards	84		(30)			114
Dividends declared	(3,891)			(3,891)
Payments to noncontrolling interests	(257)						(257)
Common stock repurchased	(199)					(199)
Other (Note 2)	(211)		(30)		(171)		(10)
Ending balance at Jun. 30, 2022	(7,260)	0	2,165	33,755	(9,043)	(35,921)	1,784
Beginning balance at Mar. 31, 2022	(8,203)	0	2,118	33,468	(9,760)	(35,924)	1,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	2,346			2,233			113
Other comprehensive earnings (losses), net of income taxes	649				717		(68)
Issuance of stock awards	50		47			3
Dividends declared	(1,946)			(1,946)
Payments to noncontrolling interests	(156)						(156)
Ending balance at Jun. 30, 2022	$ (7,260)	$ 0	$ 2,165	$ 33,755	$ (9,043)	$ (35,921)	$ 1,784

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]
Dividends declared (in dollars per share)	$ 1.25	$ 1.20	$ 2.50	$ 2.40

Background and Basis of Present

Background and Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation	Background and Basis of Presentation: Background Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United States of America), whose subsidiaries and affiliates and their licensees are primarily engaged in the manufacture and sale of cigarettes and reduced-risk products including heat-not-burn, vapor and oral nicotine products, in markets outside of the United States of America. Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries. Reduced-risk products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. "Platform 1" is the term PMI uses to refer to PMI’s reduced-risk product that uses a precisely controlled heating device into which a specially designed and proprietary tobacco unit is inserted and heated to generate an aerosol. Basis of Presentation The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a consistent basis. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not necessarily indicative of results that may be expected for the entire year. In the third quarter of 2021, PMI acquired Fertin Pharma A/S, Vectura Group plc. and OtiTopic, Inc. On March 31, 2022, PMI launched a new Wellness and Healthcare business consolidating these entities, Vectura Fertin Pharma. The operating results of this business are reported in the Wellness and Healthcare segment (formerly the Other category). For further details, see Note 2. Acquisitions and Note 9. Segment Reporting . Certain prior years' amounts have been reclassified to conform with the current year's presentation. During the first quarter of 2022, one of Fertin Pharma's product lines was moved from the Wellness and Healthcare segment to the European Union segment (reduced-risk product category). For further details, see Note 6. Goodwill and Other Intangible Assets, net . The change did not have a material impact on PMI's consolidated financial position, results of operations or cash flows in any of the periods presented. These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report on Form 10-K for the year ended December 31, 2021.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions: Purchase of Noncontrolling Interests Turkey – In the first quarter of 2022, PMI acquired the remaining 25% stake of its holding in Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş. (formerly Philsa Philip Morris Sabancı Sigara ve Tütüncülük Sanayi ve Ticaret A.Ş.) and 24.75% stake in Philip Morris Pazarlama ve Satış A.Ş. (formerly Philip Morris SA, Philip Morris Sabancı Pazarlama ve Satış A.Ş.) from its Turkish partners, Sabanci Holding for a total acquisition price including transaction costs and remaining dividend entitlements of approximately $223 million. As a result of this acquisition, PMI now owns 100% of these Turkish subsidiaries. The purchase of the remaining stakes in these holdings resulted in a decrease to PMI's additional paid-in capital of $30 million and an increase to accumulated other comprehensive losses of $171 million primarily following the reclassification of accumulated currency translation losses from noncontrolling interests to PMI’s accumulated other comprehensive losses during the first quarter of 2022. Business Combinations AG Snus - On May 6, 2021, PMI acquired 100% of AG Snus Aktieselskab ("AG Snus"), a company based in Denmark, and its Swedish subsidiary Tobacco House of Sweden AB fully owned by AG Snus, which operates in the oral tobacco (i.e. snus) and modern oral (i.e. nicotine pouches) product categories. The purchase price was $28 million in cash, net of cash acquired, with additional contingent payments of up to $10 million, primarily relating to product development and performance targets over a less than two-year period. The operating results of AG Snus are included in the European Union segment, and were not material. Fertin Pharma – On September 15, 2021, PMI acquired 100% of Fertin Pharma A/S (“Fertin Pharma”), a company based in Denmark. Fertin Pharma is a developer and manufacturer of pharmaceutical and well-being products based on oral and intra-oral delivery systems. The acquisition was funded with existing cash. The total consideration of $821 million (DKK 5.2 billion) included cash of $580 million and the payment of $241 million related to the settlement of Fertin Pharma’s indebtedness. The purchase price of $821 million was preliminarily allocated to cash ($24 million), current assets including receivables and inventories ($69 million), non-current assets including property, plant and equipment ($228 million), goodwill ($378 million), and other intangible assets ($245 million, which primarily consisted of customer relationships, developed technology, and in process research and development ("IPR&D")), partially offset by current liabilities ($44 million, which primarily consisted of accrued liabilities and accounts payable) and non-current liabilities ($79 million, primarily deferred income tax). Goodwill is primarily attributable to future growth opportunities provided by acquired R&D capabilities and any intangibles that did not qualify for separate recognition. The goodwill is not deductible for income tax purposes. The amortizable intangible assets are being amortized over their estimated useful lives of 8 to 19 years. During the six months ended June 30, 2022, PMI did not record any measurement period adjustments to the preliminary purchase price allocation. The purchase price allocation is preliminary and continues to be subject to refinement. Vectura – During the third quarter and up to September 15, 2021, PMI acquired a controlling interest of 74.77% of the total issued shares in Vectura Group plc (“Vectura”), an inhaled therapeutics company based in the United Kingdom. The shares were acquired through a series of open market purchases and acceptances of the tender offer at a price of 165 pence per share. As a result of additional acceptances of the offer and the exercise of the right to acquire compulsorily the Vectura shares, in accordance with the applicable English law, PMI completed the acquisition of 100% of Vectura in the fourth quarter of 2021. The acquisition was funded with existing cash from a designated account operated solely for the purpose of funding this acquisition. The total purchase price of $1,384 million (GBP 1.0 billion) for 100% of the Vectura shares was preliminarily allocated to cash ($136 million), current assets including receivables and inventories ($89 million), non-current assets including property, plant and equipment ($67 million), goodwill ($590 million), and other intangible assets ($719 million, which primarily consisted of developed technology, and IPR&D), partially offset by current liabilities ($100 million, primarily accrued liabilities), and non-current liabilities ($117 million, primarily deferred income tax). Goodwill is primarily attributable to future growth opportunities provided by acquired R&D capabilities and any intangibles that did not qualify for separate recognition. The goodwill is not deductible for income tax purposes. The amortizable intangible assets are being amortized over their estimated useful lives of 3 to 15 years. During the six months ended June 30, 2022, PMI did not record any measurement period adjustments to the preliminary purchase price allocation. PMI is still assessing information received, as of the acquisition date and through the period ended June 30, 2022, relating to the valuation assumptions utilized for certain intangible assets of Vectura and expects to complete this process prior to the end of the measurement period in September 2022. This assessment may result in a measurement period reduction and/or impairment of these intangible assets. Pro forma results of operations for the above business combinations have not been presented as the aggregate impact is not material to PMI's consolidated statements of earnings. Asset Acquisition On August 9, 2021, PMI acquired 100% of OtiTopic, Inc., a U.S. respiratory drug development company with a late-stage dry powder inhalation aspirin treatment for acute myocardial infarction. The transaction price was $38 million in cash, plus transaction costs, with additional contingent payment of $13 million, primarily related to certain key milestones that PMI deemed probable. Additionally, PMI may owe up to $25 million in future additional contingent payments dependent upon the achievement of certain milestones. PMI accounted for this transaction as an asset acquisition since the IPR&D of the dry powder inhalation aspirin treatment represented substantially all of the fair value of the gross assets acquired. At the date of acquisition, PMI determined that the acquired IPR&D had no alternative future use. As a result, PMI recorded a charge of $51 million to research and development costs within marketing, administration and research costs in the third quarter of 2021. As previously discussed in Note 1. Background and Basis of Presentation on March 31, 2022, PMI launched a new Wellness and Healthcare business, Vectura Fertin Pharma, which consolidates Fertin Pharma, Vectura and OtiTopic, Inc. into one operating segment.

War in Ukraine

War in Ukraine	6 Months Ended
	Jun. 30, 2022
Unusual or Infrequent Items, or Both [Abstract]
War in Ukraine	War in Ukraine: In February 2022, the Russian Federation launched a military action against Ukraine. Since the onset of the war in Ukraine, PMI's main priority has been the safety and security of its more than 1,300 employees and their families in the country. Ukraine PMI temporarily suspended its operations in Ukraine, including the closing of its factory in Kharkiv at the end of February 2022. While the effects of the war are unpredictable and could trigger impairment reviews for long-lived assets, as of June 30, 2022, PMI is unable to estimate the information required to perform impairment analyses (i.e., forecast of revenues, manufacturing and commercial plans). PMI is not aware of any major damage to its production facilities, inventories or other assets in Ukraine. As a result, PMI has not recorded an impairment of long-lived assets. As of June 30, 2022, PMI’s Ukrainian operations had approximately $456 million in total assets, excluding intercompany balances. These total assets included $70 million, $304 million and $41 million in receivables, inventories and property, plant and equipment, respectively. Russia PMI has suspended its planned investments in the Russian Federation including all new product launches and commercial, innovation, and manufacturing investments. PMI has also taken steps to scale down its manufacturing operations in Russia amid ongoing supply chain disruptions and the evolving regulatory environment and is working on options to exit the Russian market in an orderly manner. As a result of PMI continuing operations within Russia as of June 30, 2022, it has not recorded an impairment of long-lived and other assets. However, PMI recorded specific asset write downs as referred to in the table below. PMI’s Russian operations as of June 30, 2022 had approximately $2.5 billion in total assets, excluding intercompany balances. These total assets included $730 million, $679 million, $501 million and $161 million in receivables, inventories, property, plant and equipment and goodwill respectively. In addition, there was approximately $317 million of cumulative foreign currency translation losses reflected in accumulated other comprehensive losses in the condensed consolidated statement of stockholders’ equity as of June 30, 2022. As of June 30, 2022, PMI recorded in its condensed consolidated statements of earnings pre-tax charges related to circumstances driven by the war as follows: (in millions) For the Six Months Ended June 30, 2022 For the Three Months Ended June 30, 2022 Cost of sales Marketing, administration and research costs Total Cost of sales Marketing, administration and research costs Total Ukraine 1 $ 25 $ 26 $ 51 $ 14 $ 10 $ 24 Russia 2 21 50 71 6 50 56 Total $ 46 $ 76 $ 122 $ 20 $ 60 $ 80 1 The charges were primarily due to an inventory write down, additional allowance for receivables and the cost of PMI’s humanitarian efforts, which includes salary continuation for its employees. 2 The charges were primarily due to machinery and inventory write downs related to the commercial decisions noted above. PMI will continue to monitor the situation as it evolves and will determine if further charges are needed.

Stock Plans

Stock Plans	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Plans	Stock Plans: In May 2022, PMI’s shareholders approved the Philip Morris International Inc. 2022 Performance Incentive Plan (the “2022 Plan”). The 2022 Plan replaced the 2017 Performance Incentive Plan, and there will be no additional grants under the replaced plan. Under the 2022 Plan, PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity awards. Up to 25 million shares of PMI’s common stock may be issued under the 2022 Plan. At June 30, 2022, shares available for grant under the 2022 Plan were 24,980,480. In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the “2017 Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-Employee Directors Plan. At June 30, 2022, shares available for grant under the plan were 894,346. Restricted share unit (RSU) awards During the six months ended June 30, 2022 and 2021, shares granted to eligible employees and the weighted-average grant date fair value per share related to RSU awards were as follows: Number of Weighted-Average Grant Date Fair Value Per RSU Award Granted 2022 1,575,500 $ 104.99 2021 1,981,480 $ 81.91 Compensation expense related to RSU awards was as follows: Compensation Expense Related to RSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 $ 74 $ 35 2021 $ 73 $ 33 As of June 30, 2022, PMI had $224 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58. During the six months ended June 30, 2022, 1,508,880 RSU awards vested. The grant date fair value of all the vested awards was approximately $118 million. The total fair value of RSU awards that vested during the six months ended June 30, 2022 was approximately $165 million. Performance share unit (PSU) awards During the six months ended June 30, 2022 and 2021, PMI granted PSU awards to certain executives. The PSU awards require the achievement of certain performance metrics, which are predetermined at the time of grant, typically over a three-year performance cycle. The performance metrics for such PSU's granted during the six months ended June 30, 2022 consisted of PMI's Total Shareholder Return ("TSR") relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and a Sustainability Index, which consists of two drivers: • Product Sustainability (20% weight) measuring progress on PMI's efforts to maximize the benefits of smoke-free products, purposefully phase out cigarettes, seek net positive impact in wellness and healthcare, and reduce post-consumer waste; and • Operational Sustainability (10% weight) measuring progress on PMI's efforts to tackle climate change, preserve nature, improve the quality of life of people in its supply chain, and foster an empowered, and inclusive workplace. The performance metrics for such PSU's granted during the six months ended June 30, 2021 consisted of PMI's TSR relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and PMI’s performance against specific measures of PMI’s transformation, defined as net revenues from PMI's RRPs and any other non-combustible products as a percentage of PMI's total net revenues in the last year of the performance cycle (30% weight). The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum percentage of 200. Each such vested PSU entitles the participant to one share of common stock. An aggregate weighted PSU performance factor of 100 will result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the accumulated dividends paid on common stock during the performance cycle for the number of shares earned. During the six months ended June 30, 2022 and 2021, shares granted to eligible employee and the grant date fair value per share related to PSU awards were as follows: Number of Shares Granted Grant Date Grant Date (Per Share) (Per Share) 2022 451,790 $ 105.07 $ 143.94 2021 574,410 $ 81.86 $ 106.93 The grant date fair value of the PSU awards subject to the other performance metrics was determined by using the market price of PMI’s stock on the date of the grant. The grant date fair value of the PSU market based awards subject to the TSR performance metric was determined by using the Monte Carlo simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance metric: 2022 2021 Risk-free interest rate (a) 1.6 % 0.2 % Expected volatility (b) 28.6 % 31.7 % (a) Based on the U.S. Treasury yield curve. (b) Determined using the observed historical volatility. Compensation expense related to PSU awards was as follows: Compensation Expense Related to PSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 $ 31 $ 10 2021 $ 46 $ 34 As of June 30, 2022, PMI had $67 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the performance cycle of the awards, or upon death, disability or reaching the age of 58. During the six months ended June 30, 2022, 669,960 PSU awards vested. The grant date fair value of all the vested awards was approximately $54 million. The total fair value of PSU awards that vested during the six months ended June 30, 2022 was approximately $74 million.

Benefit Plans

Benefit Plans	6 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans: Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed by local statutory requirements. In addition, PMI provides health care and other benefits to substantially all U.S. retired employees and certain non-U.S. retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans. Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Net pension costs (income) $ (49) $ (2) $ (24) $ (1) Net postemployment costs 54 53 27 25 Net postretirement costs 4 4 2 3 Total pension and other employee benefit costs $ 9 $ 55 $ 5 $ 27 Pension Plans Components of Net Periodic Benefit Cost Net periodic pension cost consisted of the following: Pension (1) For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Service cost $ 119 $ 147 $ 59 $ 72 Interest cost 38 25 18 12 Expected return on plan assets (180) (186) (88) (91) Amortization: Net loss 94 158 46 78 Prior service cost (1) 1 — — Net periodic pension cost $ 70 $ 145 $ 35 $ 71 (1) Primarily non-U.S. based defined benefit retirement plans. Employer Contributions PMI makes, and plans to make, contributions, to the extent that they are tax deductible and meet specific funding requirements of its funded pension plans. Employer contributions of $60 million, excluding refunds, were made to the pension plans during the six months ended June 30, 2022. During the second quarter of 2022, PMI received a cash refund of $123 million from one of its pension plans due to a change in discount rate and value of assets that resulted in the overfunding of the plan. Currently, PMI anticipates making additional contributions during the remainder of 2022 of approximately $53 million to its pension plans, based on current tax and benefit laws. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on pension assets, or changes in interest and currency rates.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, net	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, net	Goodwill and Other Intangible Assets, net: The movements in goodwill were as follows: (in millions) European Union Eastern Europe Middle East & Africa South & Southeast Asia East Asia & Australia Americas Wellness and Healthcare Total Balances, December 31, 2021 $ 1,397 $ 295 $ 79 $ 2,828 $ 539 $ 611 $ 931 $ 6,680 Changes due to: Currency (98) (17) (1) (141) (31) 8 (82) (362) Balances, June 30, 2022 $ 1,299 $ 278 $ 78 $ 2,687 $ 508 $ 619 $ 849 $ 6,318 At June 30, 2022, goodwill primarily reflects PMI’s business combinations in Colombia, Greece, Indonesia, Mexico, Pakistan, the Philippines and Serbia, as well as the preliminary purchase price allocation of Fertin Pharma A/S and Vectura Group plc., which were acquired in September 2021. As discussed in Note 1. Background and Basis of Presentation , during the first quarter of 2022, one of Fertin Pharma's product lines was moved from the Wellness and Healthcare segment to the European Union segment. As a result, the December 31, 2021 opening goodwill balance in the table above included a reclassification of $24 million from the Wellness and Healthcare segment to the European Union segment. Details of other intangible assets were as follows: June 30, 2022 December 31, 2021 (in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Non-amortizable intangible assets $ 1,289 $ 1,289 $ 1,312 $ 1,312 Amortizable intangible assets: Trademarks 11 years 1,159 $ 647 512 1,201 $ 639 562 Developed technology, including patents 12 years 820 98 722 859 63 796 Other (1) 11 years 226 93 133 238 90 148 Total other intangible assets $ 3,494 $ 838 $ 2,656 $ 3,610 $ 792 $ 2,818 (1) Primarily includes distribution networks and customer relationships. Non-amortizable intangible assets substantially consist of trademarks from PMI’s acquisitions in Indonesia and Mexico, as well as the preliminary purchase price allocation associated with PMI's business combinations in 2021 (primarily in-process research and development). The decrease since December 31, 2021 was due to currency movements of ($23 million). The decrease in the gross carrying amount of amortizable intangible assets from December 31, 2021, was mainly due to currency movements of ($94 million). The change in the accumulated amortization from December 31, 2021, was mainly due to the 2022 amortization of $74 million, partially offset by currency movements of ($28 million). Amortization expense for each of the next five years is estimated to be $145 million or less, assuming no additional transactions occur that require the amortization of intangible assets. During the second quarter of 2022, PMI completed its annual review of goodwill and non-amortizable intangible assets for potential impairment, and no impairment charges were required as a result of this review. However, there are still risks related to PMI’s Russian reporting unit’s assets as the fair value of these assets is difficult to predict due to the volatility in foreign currency and commodity markets, supply chain, and current economic, political and social conditions. For more information see Note 3. War in Ukraine . Each of PMI’s reporting units had fair values substantially in excess of its carrying value with the exception of the Wellness and Healthcare reporting unit, which had less than 20% excess of fair value over its carrying value. The Wellness and Healthcare reporting unit's fair value was determined using the discounted cash flow model. PMI will continue to monitor this reporting unit as any changes in assumptions, estimates or market factors could result in a future impairment. For information regarding PMI’s developed technology definite-lived intangible assets see Note 2. Acquisitions

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments: Overview PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes certain financial instruments to manage foreign currency and interest rate exposures. Derivative financial instruments are used by PMI principally to reduce exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the consolidated balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Financial instruments qualifying for hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings. PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Both foreign exchange contracts and interest rate contracts are collectively referred to as derivative contracts ("derivative contracts"). The primary currencies to which PMI is exposed include the Euro, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble and Swiss franc. At June 30, 2022, PMI had contracts with aggregate notional amounts of $29.1 billion of which $5.0 billion related to cash flow hedges, $6.7 billion related to hedges of net investments in foreign operations, $1.0 billion related to fair value hedges and $16.4 billion related to other derivatives that primarily offset currency exposures on intercompany financing and anticipated acquisition related transactions. The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, were as follows: Derivative Assets Derivative Liabilities Fair Value Fair Value At At At At (in millions) Balance Sheet Classification June 30, 2022 December 31, 2021 Balance Sheet Classification June 30, 2022 December 31, 2021 Derivative contracts designated as hedging instruments Other current assets $ 388 $ 173 Other accrued liabilities $ 8 $ 34 Other assets 297 22 Income taxes and other liabilities 75 190 Derivative contracts not designated as hedging instruments Other current assets 111 37 Other accrued liabilities 151 75 Other assets 4 — Income taxes and other liabilities 19 — Total gross amount derivatives contracts presented in the condensed consolidated balance sheets $ 800 $ 232 $ 253 $ 299 Gross amounts not offset in the condensed consolidated balance sheets Financial instruments (148) (126) (148) (126) Cash collateral received/pledged (636) (93) (68) (151) Net amount $ 16 $ 13 $ 37 $ 22 PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates. PMI’s derivative contracts have been classified within Level 2 at June 30, 2022 and December 31, 2021. For the six months ended June 30, 2022 and 2021, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Six Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2022 2021 2022 2021 2022 2021 Derivative contracts designated as hedging instruments: Cash flow hedges $ 355 $ 89 Net revenues $ 81 $ 17 Cost of sales — — Marketing, administration and research costs (10) (12) Interest expense, net (7) (7) Fair value hedges Interest expense, net $ (57) $ — Net investment hedges (a) 530 192 Interest expense, net (b) 68 82 Derivative contracts not designated as hedging instruments: Interest expense, net 43 25 Marketing, administration and research costs (c) 65 196 Total $ 885 $ 281 $ 64 $ (2) $ 119 $ 303 (a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar. (b) Represent the gains for amounts excluded from the effectiveness testing (c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are primarily offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged For the three months ended June 30, 2022 and 2021, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Three Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2022 2021 2022 2021 2022 2021 Derivative contracts designated as hedging instruments: Cash flow hedges $ 225 $ (1) Net revenues $ 64 $ 17 Cost of sales — — Marketing, administration and research costs (7) 6 Interest expense, net (4) (4) Fair value hedges Interest expense, net $ (20) $ — Net investment hedges (a) 425 (126) Interest expense, net (b) 35 40 Derivative contracts not designated as hedging instruments: Interest expense, net 35 14 Marketing, administration and research costs (c) 66 (91) Total $ 650 $ (127) $ 53 $ 19 $ 116 $ (37) (a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar (b) Represent the gains for amounts excluded from the effectiveness testing (c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are primarily offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged Cash Flow Hedges PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to certain forecasted transactions. Gains and losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses until the underlying hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of June 30, 2022, PMI has hedged forecasted transactions for periods not exceeding the next eighteen months with the exception of one derivative contract that expires in May 2024. The impact of these hedges is primarily included in operating cash flows on PMI’s condensed consolidated statements of cash flows. Fair Value Hedges PMI has entered into fixed-to-floating interest rate contracts, designated as fair value hedges to minimize exposure to changes in the fair value of fixed rate U.S. dollar-denominated debt that results from fluctuations in benchmark interest rates. For derivative contracts that are designated and qualify as fair value hedges, the gain or loss on the derivative, as well as the offsetting gain or loss on the hedged items attributable to the hedged risk, is recognized in current earnings. The carrying amount of the debt hedged, which includes the cumulative adjustment for fair value gains/losses, as of June 30, 2022 was $938 million, and is recorded in long-term debt in the condensed consolidated balance sheets. The cumulative amount of fair value gains/(losses) included in the carrying amount of the debt hedged was $56 million as of June 30, 2022. Hedges of Net Investments in Foreign Operations PMI designates derivative contracts and certain foreign currency denominated debt instruments as net investment hedges, primarily of its Euro net assets. For the six months ended June 30, 2022 and 2021, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $258 million and $110 million, respectively. For the three months ended June 30, 2022 and 2021, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $192 million and $(71) million, respectively. The premiums paid for, and settlements of, net investment hedges are included in investing cash flows on PMI’s condensed consolidated statements of cash flows. Other Derivatives PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain subsidiaries, third-party loans and anticipated acquisition related transactions. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses) relating to these contracts are reported in PMI’s condensed consolidated statements of earnings. Acquisition related transactions are included in investing cash flows on PMI’s condensed consolidated statements of cash flows. Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Gain/(loss) as of beginning of period $ 4 $ (85) $ 105 $ 12 Derivative (gains)/losses transferred to earnings (55) 2 (46) (19) Change in fair value 301 77 191 1 Gain/(loss) as of June 30, $ 250 $ (6) $ 250 $ (6) At June 30, 2022, PMI expects $141 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings impact of the respective hedged transactions. Contingent Features PMI’s derivative instruments do not contain contingent features. Credit Exposure and Credit Risk PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as counterparties. Other Investments

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share: Basic and diluted earnings per share (“EPS”) were calculated using the following: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Net earnings attributable to PMI $ 4,564 $ 4,590 $ 2,233 $ 2,172 Less distributed and undistributed earnings attributable to share-based payment awards 13 14 7 6 Net earnings for basic and diluted EPS $ 4,551 $ 4,576 $ 2,226 $ 2,166 Weighted-average shares for basic EPS 1,550 1,558 1,551 1,558 Plus contingently issuable performance stock units (PSUs) 2 2 1 2 Weighted-average shares for diluted EPS 1,552 1,560 1,552 1,560 Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are included in PMI’s earnings per share calculation pursuant to the two-class method. For the 2022 and 2021 computations, there were no antidilutive stock awards.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting: PMI’s subsidiaries and affiliates are primarily engaged in the manufacture and sale of cigarettes and RRPs, including heat-not-burn, vapor and oral nicotine products, in markets outside of the United States of America. PMI's segments are generally organized by geographic region and managed by segment managers who are responsible for the operating and financial results of the regions inclusive of combustible and reduced-risk product categories sold in the region. PMI currently has six geographical segments: the European Union; Eastern Europe; Middle East & Africa; South & Southeast Asia; East Asia & Australia; and Americas; as well as the Wellness and Healthcare segment. The Wellness and Healthcare segment consists of the operating results of PMI's new business, Vectura Fertin Pharma. For further details, see Note 2. Acquisitions . PMI records net revenues and operating income to its geographical segments based upon the geographic area in which the customer resides. PMI’s chief operating decision maker evaluates geographical segment performance and allocates resources based on regional operating income, which includes results from all product categories sold in each region. Business operations in the Wellness and Healthcare segment are managed and evaluated separately. PMI disaggregates its net revenue from contracts with customers by both geographic location and product category for each of PMI's six geographical segments. For the new Wellness and Healthcare business, Vectura Fertin Pharma discussed above, net revenues from contracts with customers are included in the Wellness and Healthcare segment. PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Segment data were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Net revenues: European Union $ 6,155 $ 6,058 $ 3,143 $ 3,149 Eastern Europe 1,624 1,691 898 895 Middle East & Africa 1,997 1,361 1,006 560 South & Southeast Asia 2,157 2,219 1,034 1,046 East Asia & Australia 2,610 2,986 1,206 1,514 Americas 893 864 469 430 Wellness and Healthcare 142 — 76 — Net revenues $ 15,578 $ 15,179 $ 7,832 $ 7,594 Operating income (loss): European Union $ 3,046 $ 3,131 $ 1,519 $ 1,641 Eastern Europe 435 575 291 314 Middle East & Africa 1,019 351 498 16 South & Southeast Asia 751 860 306 331 East Asia & Australia 917 1,410 346 715 Americas 251 246 130 112 Wellness and Healthcare (65) — (34) — Operating income $ 6,354 $ 6,573 $ 3,056 $ 3,129 PMI's net revenues by product category were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Net revenues: Combustible products: European Union $ 3,763 $ 4,113 $ 1,954 $ 2,162 Eastern Europe 1,042 1,047 585 555 Middle East & Africa 1,862 1,307 933 527 South & Southeast Asia 2,147 2,216 1,029 1,045 East Asia & Australia 1,129 1,259 528 611 Americas 876 840 460 418 Total combustible products $ 10,819 $ 10,781 $ 5,489 $ 5,318 Reduced-risk products: European Union $ 2,392 $ 1,945 $ 1,189 $ 987 Eastern Europe 582 644 313 340 Middle East & Africa 135 54 73 33 South & Southeast Asia 10 3 5 1 East Asia & Australia 1,481 1,727 678 903 Americas 17 24 9 12 Total reduced-risk products $ 4,617 $ 4,398 $ 2,267 $ 2,276 Wellness and Healthcare: Wellness and Healthcare $ 142 $ — $ 76 $ — Total PMI net revenues $ 15,578 $ 15,179 $ 7,832 $ 7,594 Note: Sum of product categories or Regions might not foot to total PMI due to roundings. Items affecting the comparability of results from operations were as follows: • Charges related to the war in Ukraine - See Note 3. War in Ukraine for details of the $122 million and $80 million pre-tax charges in the Eastern Europe segment for the six months and three months ended June 30, 2022, respectively. • Saudi Arabia customs assessments - See Note 10. Contingencies for the details of the $246 million reduction in net revenues of combustible products included in the Middle East & Africa segment for the six months and three months ended June 30, 2021. • Asset impairment and exit costs - See Note 17. Asset Impairment and Exit Costs for details of the $127 million and $79 million pre-tax charge and a breakdown of these costs by segment for the six months and three months ended June 30, 2021, respectively. Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and cigarillos, and do not include reduced-risk products. Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's heated tobacco units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include PMI's e-vapor and oral nicotine products. Net revenues related to wellness and healthcare products primarily consist of operating revenues generated from the sale of inhaled therapeutics, and oral and intra-oral delivery systems that are included in the operating results of PMI's new Wellness and Healthcare business, Vectura Fertin Pharma.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies: Tobacco-Related Litigation Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend, as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending tobacco-related litigation could encourage the commencement of additional litigation. Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Brazil, Canada and Nigeria, range into the billions of U.S. dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. Much of the tobacco-related litigation is in its early stages, and litigation is subject to uncertainty. However, as discussed below, we have to date been largely successful in defending tobacco-related litigation. We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 10. Contingencies , while it is reasonably possible that an unfavorable outcome in a case may occur, after assessing the information available to it (i) management has not concluded that it is probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of loss for any of the pending tobacco-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for unfavorable outcomes in these cases, if any. Legal defense costs are expensed as incurred. It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended. However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so. CCAA Proceedings and Stay of Tobacco-Related Cases Pending in Canada As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson & Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA order made by the Ontario Superior Court on March 22, 2019 authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course after the CCAA filing, including obligations to employees, vendors, and suppliers. As further described in Item 8, Note 20. Deconsolidation of RBH of PMI's Annual Report on Form 10-K for the year ended December 31, 2021, RBH's financial results have been deconsolidated from our consolidated financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30, 2022 of all tobacco-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria), namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented below under the caption “ Stayed Litigation — Canada .” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation, it is anticipated that the court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau and the Blais cases so long as the comprehensive stay of all tobacco-related litigation in Canada remains in effect and that the time period to file the application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases were incorrect, the CCAA proceedings will provide a forum for RBH to seek resolution through a plan of arrangement or compromise of all tobacco-related litigation pending in Canada. It is not possible to predict the resolution of the underlying legal proceedings or the length of the CCAA process. Stayed Litigation — Canada Smoking and Health Litigation — Canada In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada , filed in November 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiffs, an anti-smoking organization and an individual smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain smoking-related diseases. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and found that the class members’ compensatory damages totaled approximately CAD 15.5 billion, including pre-judgment interest (approximately $12 billion). The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion, including pre-judgment interest (approximately $2.4 billion)). In addition, the trial court awarded CAD 90,000 (approximately $69,700) in punitive damages, allocating CAD 30,000 (approximately $23,200) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $175 million) to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco Canada Ltd. to furnish security totaling CAD 758 million (approximately $586 million) in installments through June 2017. JTI Macdonald Corp. was not required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion including interest (approximately $10.5 billion) due to the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH (approximately CAD 2.7 billion, including pre-judgment interest (approximately $2.1 billion)). The Court of Appeal upheld the trial court’s findings that defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais case, approximately CAD 1.1 billion (approximately $852 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD 257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax, as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment. In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $101 million) in punitive damages, allocating CAD 46 million (approximately $35.6 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD 57 million including interest (approximately $44 million) to RBH. See the Blais description above and Item 8, Note 20. Deconsolidation of RBH in PMI's Annual Report on Form 10-K for the year ended December 31, 2021 for further detail concerning the security order pertaining to both Létourneau and Blais cases and the impact of the decision on PMI’s financial statements. RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on several grounds including the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking; (ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to all class members given the individual differences between class members. In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada , filed June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada , filed July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, emphysema, heart disease, or cancer, as well as restitution of profits. In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia, Canada , filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have not been properly served with the complaint. In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada , filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada , filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim. In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as restitution of profits. Health Care Cost Recovery Litigation — Canada In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting from a “tobacco related wrong.” In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of Justice, Toronto, Canada , filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, St. Johns, Canada , filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec, Canada , filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench Alberta, Canada , filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges, Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada , filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench, Judicial Centre of Saskatchewan, Canada , filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada , filed September 10, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Nova Scotia, Canada , filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” __________ The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as of June 30, 2022, and June 30, 2021:¹ Type of Case Number of Cases Pending as of June 30, 2022 Number of Cases Pending as of June 30, 2021 Individual Smoking and Health Cases 40 44 Smoking and Health Class Actions 9 9 Health Care Cost Recovery Actions 17 17 Label-Related Class Actions — — Individual Label-Related Cases 5 4 Public Civil Actions 1 2 Since 1995, when the first tobacco-related litigation was filed against a PMI entity, 526 Smoking and Health, Label-Related, Health Care Cost Recovery, and Public Civil Actions in which we and/or one of our subsidiaries and/or indemnitees were a defendant have been terminated in our favor. Fourteen cases have had decisions in favor of plaintiffs. Ten of these cases have subsequently reached final resolution in our favor and four remain on appeal. ______ ¹ Includes cases pending in Canada. The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff: Date Location of Type of Verdict Post-Trial May 27, 2015 Canada/Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais Class Action On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Blais class on liability and found the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $12 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion including pre-judgment interest (approximately $2.4 billion)). The trial court awarded CAD 90,000 (approximately $69,700) in punitive damages, allocating CAD 30,000 (approximately $23,200) to our subsidiary. The trial court ordered defendants to pay CAD 1 billion (approximately $774 million) of the compensatory damage award, CAD 200 million (approximately $155 million) of which is our subsidiary’s portion, into a trust within 60 days. In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “ Stayed Litigation — Canada ” for further detail.) Date Location of Type of Verdict Post-Trial May 27, 2015 Canada/Cecilia Létourneau Class Action On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Létourneau class on liability and awarded a total of CAD 131 million (approximately $101 million) in punitive damages, allocating CAD 46 million (approximately $35.6 million) to RBH. The trial court ordered defendants to pay the full punitive damage award into a trust within 60 days. The court did not order the payment of compensatory damages. In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “ Stayed Litigation — Canada ” for further detail.) Date Location of Type of Verdict Post-Trial August 5, 2016 Argentina/Hugo Lespada Individual Action On August 5, 2016, the Civil Court No. 14 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded him ARS 110,000 (approximately $848), plus interest, in compensatory and moral damages. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes. On August 23, 2016, our subsidiary filed its notice of appeal. On October 31, 2017, the Civil and Commercial Court of Appeals of Mar del Plata ruled that plaintiff's claim was barred by the statute of limitations and it reversed the trial court's decision. On May 17, 2021 plaintiff filed a federal extraordinary appeal. On November 1, 2021, the Supreme Court of the Province of Buenos Aires dismissed plaintiff's federal extraordinary appeal. On November 10, 2021, plaintiff filed a direct appeal before the Federal Supreme Court. Date Location of Type of Verdict Post-Trial June 17, 2021 Argentina/Claudia Milano Individual Action On June 17, 2021, the Civil Court No. 9 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded her smoking cessation treatments, ARS 150,000 (approximately $1,157), in compensatory and moral damages, and ARS 4,000,000 (approximately $30,848) in punitive damages, plus interest and costs. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes. On July 2, 2021, our subsidiary filed its notice of appeal. In addition, plaintiff filed an appeal challenging the dismissal of the claim for psychological damages. As required by local law, our subsidiary deposited the damages awarded, plus interest and costs, in total ARS 6,114,428 (approximately $47,154), into a court escrow account. Our subsidiary challenged the amount determined by the court. The Civil and Commercial Court of Appeals of Mar del Plata granted our subsidiary's challenge to the escrow amount determined by the trial court. As a result, on December 16, 2021, ARS 893,428 (approximately $6,890) was returned to our subsidiary. If our subsidiary ultimately prevails, the remaining deposited amounts will be returned to our subsidiary. On May 31, 2022, the Civil and Commercial Court of Appeals of Mar del Plata ruled that the statute of limitations barred plaintiff's claim and reversed the trial court's decision. On June 15, 2022, plaintiff filed an extraordinary appeal. Pending claims related to tobacco products generally fall within the following categories: Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause, assumption of the risk, contributory negligence, and statute of limitations. As of June 30, 2022, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows: • 40 cases brought by individual plaintiffs in Argentina (31), Brazil (1), Canada (2), Chile (2), the Philippines (1), Turkey (1) and Scotland (1), as well as 1 case brought by an individual plaintiff in the United States District Court for the District of Oregon in May 2021 (See information regarding the provisions of the 2008 Share Distribution Agreement between PMI and Altria that provide for indemnities to PMI for certain liabilities concerning tobacco products under the caption " Tobacco-Related Litigation " described above), compared with 44 such cases on June 30, 2021; and • 9 cases brought on behalf of classes of individual plaintiffs, compared with 9 such cases on June 30, 2021. The class actions pending in Canada are described above under the caption “ Smoking and Health Litigation — Canada. ” Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special duty, frau

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes: Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets. PMI’s effective tax rates for the six months and three months ended June 30, 2022 were 20.0% and 20.3%, respectively. PMI's effective tax rates for the six months and three months ended June 30, 2021 were 21.7% and 22.0%, respectively. The effective tax rate for the six months ended June 30, 2022, was favorably impacted by a reduction in deferred tax liabilities related to pension plan assets ($40 million), as well as a decrease in deferred tax liabilities related to the fair value adjustment of equity securities held by PMI ($13 million). For further details, see Note 14. Related Parties - Equity Investments and Other . PMI estimates that its full-year 2022 effective tax rate will be 21% to 22%, excluding discrete tax events. Changes in currency exchange rates, earnings mix by taxing jurisdiction or future regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant judgment is required in determining income tax provisions and in evaluating tax positions. PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of limitations remains open for the years 2017 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from 3 to 5 years. In October 2021, a subsidiary of PMI in Indonesia, PT Hanjaya Mandala Sampoerna Tbk ("HMS"), received a tax assessment in the amount of 3.8 trillion Indonesian rupiah (approximately $260 million in the period of payment) primarily relating to corporate income taxes on domestic and other intercompany transactions for the years 2017 to 2019. HMS paid the assessment in the fourth quarter of 2021 in order to avoid potential penalties and filed an objection letter with the tax office in January 2022. The amount paid was included in other assets in PMI’s condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, and negatively impacted net cash provided by operating activities in the consolidated statements of cash flows in the period of payment. It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits along with related interest and penalties. An estimate of any possible change cannot be made at this time.

Indebtedness

Indebtedness	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Indebtedness	Indebtedness: Short-term Borrowings: PMI's short-term borrowings, consisting of commercial paper and bank loans to certain PMI subsidiaries at June 30, 2022, and bank loans to certain PMI subsidiaries at December 31, 2021, had a carrying value of $1,558 million and $225 million, respectively. The fair values of PMI’s short-term borrowings, based on current market interest rates, approximate carrying value. Long-term Debt: At June 30, 2022 and December 31, 2021, PMI’s long-term debt consisted of the following: (in millions) June 30, 2022 December 31, 2021 U.S. dollar notes, 0.875% to 6.375% (average interest rate 3.261%), due through 2044 $ 18,853 $ 19,397 Foreign currency obligations: Euro notes, 0.125% to 3.125% (average interest rate 1.995%), due through 2039 7,149 7,687 Swiss franc note, 1.625%, due 2024 263 273 Other (average interest rate 3.496%), due through 2029 (a) 229 224 Carrying value of long-term debt 26,494 27,581 Less current portion of long-term debt 4,149 2,798 $ 22,345 $ 24,783 (a) Includes mortgage debt in Switzerland as well as $82 million and $71 million in finance leases at June 30, 2022 and December 31, 2021, respectively. The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates currently available to PMI for issuances of debt with similar terms and remaining maturities. At June 30, 2022, the fair value of PMI's outstanding long-term debt, excluding the aforementioned finance leases, was as follows: (in millions) June 30, 2022 Level 1 $ 23,930 Level 2 153 For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2021. Revolving Credit Facilities: At June 30, 2022, PMI's total committed revolving credit facilities were as follows: (in billions) Type Committed 364-day revolving credit, expiring January 31, 2023 1.8 Multi-year revolving credit, expiring February 10, 2026 (1) 2.0 Multi-year revolving credit, expiring September 29, 2026 (2) 2.5 Total facilities $ 6.3 (1) On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion. (2) Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails to achieve, certain specified targets. At June 30, 2022, there were no borrowings under these committed revolving credit facilities, and the entire committed amounts were available for borrowing. Financing of the Swedish Match Offer In connection with PMI’s all-cash recommended public offer to the shareholders of Swedish Match AB ("Swedish Match"), a public limited liability company organized under the laws of Sweden, for all the outstanding shares of Swedish Match, on May 11, 2022, PMI entered into a credit agreement relating to a 364-day senior unsecured bridge facility. The facility provided for borrowings up to an aggregate principal amount of $17 billion, expiring 364 days after the occurrence of certain events unless extended. On June 23, 2022, PMI entered into a new €5.5 billion (approximately $5.8 billion at the date of signing) senior unsecured term loan credit agreement consisting of a €3.0 billion (approximately $3.2 billion at the date of signing) tranche expiring three years after the occurrence of certain events and a €2.5 billion (approximately $2.6 billion at the date of signing) tranche expiring on June 23, 2027. In connection with the term loan facility, the aggregate principal amount of commitments under the 364-day senior unsecured bridge facility was reduced from $17 billion to $11 billion. As of June 30, 2022, there were no borrowings under these two facilities. If drawn upon, the proceeds under the bridge facility and the term loan facility will be used, directly or indirectly, to finance the offer, including, the payment of related fees and expenses.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Losses	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Losses	Accumulated Other Comprehensive Losses: PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following: (Losses) Earnings At At At (in millions) June 30, 2022 December 31, 2021 June 30, 2021 Currency translation adjustments $ (6,558) $ (6,701) $ (6,586) Pension and other benefits (2,735) (2,880) (4,073) Derivatives accounted for as hedges 250 4 (6) Total accumulated other comprehensive losses $ (9,043) $ (9,577) $ (10,665) Reclassifications from Other Comprehensive Earnings The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period activity and reclassifications to the income statement, are shown on the condensed consolidated statements of comprehensive earnings for the six months and three months ended June 30, 2022 and 2021. For additional information, see Note 2. Acquisitions (Purchase of Noncontrolling Interests) for disclosures related to currency translation adjustments , Note 5. Benefit Plans for disclosures related to PMI's pension and other benefits and Note 7. Financial Instruments for disclosures related to derivative financial instruments.

Related Parties - Equity Invest

Related Parties - Equity Investments and Other	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Related Parties - Equity Investments and Other	Related Parties - Equity Investments and Other: Equity Method Investments: At June 30, 2022 and December 31, 2021, PMI had total equity method investments of $1,036 million and $879 million, respectively. Equity method investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or losses, dividends, capital contributions, changes in ownership interests and movements in currency translation adjustments. The carrying value of our equity method investments at June 30, 2022 and December 31, 2021, exceeded our share of the investees' book value by $902 million and $764 million, respectively. The difference between the investment carrying value and the amount of underlying equity in net assets, excluding $862 million and $728 million attributable to goodwill as of June 30, 2022 and December 31, 2021, respectively, which consists primarily of definite-lived intangible assets is being amortized on a straight-line basis. At June 30, 2022 and December 31, 2021, PMI received year-to-date dividends from equity method investees of $8 million and $176 million, respectively. PMI holds a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia (Eastern Europe segment), which as of June 30, 2022 had a carrying value of $530 million. While as of June 30, 2022, there have been no impairment indicators based on the business’ performance, there are still risks related to this investment as the fair value of these assets is difficult to predict due to the volatility in foreign currency and commodity markets, supply chain, and current economic, political and social conditions. For more information see Note 3. War in Ukraine . Additionally, there was approximately $321 million of cumulative foreign currency translation losses associated with Megapolis Distribution BV reflected in accumulated other comprehensive losses in the condensed consolidated statement of stockholders’ equity as of June 30, 2022. PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise Management et Développement des Actifs et des Ressources Holding ("MADAR Holding"), which manufactures and distributes under license some of PMI’s brands (Middle East & Africa segment). The initial investments in Megapolis Distribution BV and EITA were recorded at cost and are included in equity investments on the condensed consolidated balance sheets. Equity securities: Following the deconsolidation of RBH on March 22, 2019, PMI recorded the continuing investment in RBH, PMI's wholly owned subsidiary in Canada, at fair value of $3,280 million at the date of deconsolidation, within equity investments. For further details, see Item 8, Note 20. Deconsolidation of RBH , in PMI's Annual Report on Form 10-K for the year ended December 31, 2021. Transactions between PMI and RBH are considered to be related party transactions from the date of deconsolidation and are included in the tables below. The fair value of PMI’s other equity securities, which have been classified within Level 1, was $215 million at June 30, 2022. Unrealized pre-tax loss of $60 million ($47 million net of tax) on these equity securities was recorded in equity investments and securities (income)/loss, net on the condensed consolidated statement of earnings for the six months ended June 30, 2022. During the three months ended June 30, 2022, PMI did not record any unrealized gains or losses on equity securities in the condensed consolidated statements of earnings. Other related parties: United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC ("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the Middle East & Africa segment. PMM sells, under license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI. Godfrey Phillips India Ltd ("GPI") is one of the non-controlling interest holders in IPM India, which is a 56.3% owned PMI consolidated subsidiary in the South & Southeast Asia segment. GPI also acts as contract manufacturer and distributor for IPM India. Amounts in the tables below include transactions between these related parties. Financial activity with the above related parties: PMI’s net revenues and expenses with the above related parties were as follows: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Net revenues: Megapolis Group $ 993 $ 1,038 $ 606 $ 555 Other 554 560 263 280 Net revenues (a) $ 1,547 $ 1,598 $ 869 $ 835 Expenses: Other $ 29 $ 33 $ 17 $ 16 Expenses $ 29 $ 33 $ 17 $ 16 (a) Net revenues exclude excise taxes and VAT billed to customers. PMI’s balance sheet activity with the above related parties was as follows: (in millions) At June 30, 2022 At December 31, 2021 Receivables: Megapolis Group $ 725 $ 319 Other 243 199 Receivables $ 968 $ 518 Payables: Other $ 32 $ 25 Payables $ 32 $ 25

Sale of Accounts Receivable

Sale of Accounts Receivable	6 Months Ended
	Jun. 30, 2022
Sale of Accounts Receivable [Abstract]
Sale of Accounts Receivable	Sale of Accounts Receivable: To mitigate risk and enhance cash and liquidity management, PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing liability were not material as of June 30, 2022 and June 30, 2021. Under the non-servicing arrangements, PMI does not provide any administrative support or servicing after the trade receivables have been sold to the unaffiliated financial institutions. Cumulative trade receivables sold, including excise taxes, for the six months ended June 30, 2022 and 2021, were $5.6 billion and $5.5 billion, respectively. PMI’s operating cash flows were positively impacted by the amount of the trade receivables sold and derecognized from the condensed consolidated balance sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these arrangements as of June 30, 2022 and June 30, 2021, were $656 million, and $701 million, respectively. The net proceeds received are included in cash provided by operating activities in the condensed consolidated statements of cash flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of trade receivables within marketing, administration and research costs in the condensed consolidated statements of earnings. For the six months and three months ended June 30, 2022 and 2021, the loss on sale of trade receivables was immaterial.

Product Warranty

Product Warranty	6 Months Ended
	Jun. 30, 2022
Guarantees and Product Warranties [Abstract]
Product Warranty	Product Warranty: PMI's heat-not-burn devices and e-vapor products are subject to standard product warranties generally for a period of 12 months from the date of purchase or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in future estimates. Factors that affect product warranties may vary across markets but typically include device version mix, product failure rates, logistics and service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At June 30, 2022 and December 31, 2021, these amounts were as follows: (in millions) As of and For the Six Months Ended June 30, 2022 As of and For the Year Ended December 31, 2021 Balance at beginning of period $ 113 $ 137 Changes due to: Warranties issued 67 154 Settlements (60) (177) Currency/Other 2 (1) Balance at end of period $ 122 $ 113

Asset Impairment and Exit Costs

Asset Impairment and Exit Costs	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Asset Impairment and Exit Costs	Asset Impairment and Exit Costs: For the six months and three months ended June 30, 2022, PMI did not record any charges for asset impairment and exit costs. For the six months and three months ended June 30, 2021, PMI recorded total pre-tax asset impairment and exit costs of $127 million and $79 million, respectively. These pre-tax charges for the six months and three months ended June 30, 2021 were included in marketing, administration and research costs in the condensed consolidated statements of earnings. South Korea In 2021 PM Korea implemented a new business operating model, which required the restructuring of its current distribution agreements. As a result, PMI recorded exit costs of $26 million as of June 30, 2021, related to contract terminations and restructuring with certain distributors. The full cost of the program, which was recorded as exit costs during the year ended December 31, 2021, was $57 million. Organizational Design Optimization As part of PMI’s transformation to a smoke-free future, PMI sought to optimize its organizational design, which included the elimination, relocation and outsourcing of certain operations center and centralized activities. In January 2020, PMI commenced a multi-phase restructuring project in Switzerland. PMI initiated the employee consultation procedures, as required under Swiss law, for the impacted employees. The consultation procedures for the first two phases were completed in 2020 with the final phases initiated and completed in 2021. Additionally, since the commencement of this multi-phase restructuring project in 2020, PMI launched a voluntary separation program in Switzerland for certain eligible employees and announced the outsourcing of certain activities in Argentina, Indonesia, Poland and the United States. This multi-phase restructuring project was completed in the fourth quarter of 2021. For the six months and three months ended June 30, 2021, PMI recorded pre-tax charges of $101 million and $79 million, respectively, related to the organizational design optimization. Since inception of this multi-phase restructuring project in January 2020 through December 31, 2021, approximately 1,020 positions in total were impacted, resulting in cumulative pre-tax charges of $308 million related to the organizational design optimization program. Of this cumulative pre-tax amount, $300 million related to separation program charges and $8 million related to asset impairment charges. Asset Impairment and Exit Costs by Segment PMI recorded the following pre-tax asset impairment and exit costs by segment: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2021 2021 Separation programs: (1) European Union $ 44 $ 35 Eastern Europe 9 7 Middle East & Africa 10 8 South & Southeast Asia 13 10 East Asia & Australia 20 15 Americas 5 4 Total separation programs 101 79 Contract termination charges: East Asia & Australia 26 — Total contract termination charges 26 — Asset impairment and exit costs $ 127 $ 79 (1) Organizational design optimization pre-tax charges in 2021 were allocated across all geographical segments. Movement in Exit Cost Liabilities The movement in exit cost liabilities for the six months ended June 30, 2022 was as follows: (in millions) Liability balance, January 1, 2022 $ 142 Charges, net — Cash spent (47) Currency/other (5) Liability balance, June 30, 2022 $ 90

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Leases: The components of PMI’s lease cost were as follows for the six months and three months ended June 30, 2022 and 2021: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Operating lease cost $ 126 $ 126 $ 64 $ 66 Finance lease cost: Amortization of right-of-use assets 47 17 31 9 Short-term lease cost 30 25 16 15 Variable lease cost 11 14 5 7 Total lease cost $ 214 $ 182 $ 116 $ 97

Background and Basis of Prese_2

Background and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Derivatives	PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes certain financial instruments to manage foreign currency and interest rate exposures. Derivative financial instruments are used by PMI principally to reduce exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the consolidated balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Financial instruments qualifying for hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings. PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Both foreign exchange contracts and interest rate contracts are collectively referred to as derivative contracts ("derivative contracts").
Fair Value of Financial Instruments	PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates.

War in Ukraine (Tables)

War in Ukraine (Tables)	6 Months Ended
	Jun. 30, 2022
Unusual or Infrequent Items, or Both [Abstract]
Schedule of pretax charges related to circumstances	As of June 30, 2022, PMI recorded in its condensed consolidated statements of earnings pre-tax charges related to circumstances driven by the war as follows: (in millions) For the Six Months Ended June 30, 2022 For the Three Months Ended June 30, 2022 Cost of sales Marketing, administration and research costs Total Cost of sales Marketing, administration and research costs Total Ukraine 1 $ 25 $ 26 $ 51 $ 14 $ 10 $ 24 Russia 2 21 50 71 6 50 56 Total $ 46 $ 76 $ 122 $ 20 $ 60 $ 80 1 The charges were primarily due to an inventory write down, additional allowance for receivables and the cost of PMI’s humanitarian efforts, which includes salary continuation for its employees.

Stock Plans (Tables)

Stock Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Disclosure of share-based compensation arrangements by payment award	During the six months ended June 30, 2022 and 2021, shares granted to eligible employees and the weighted-average grant date fair value per share related to RSU awards were as follows: Number of Weighted-Average Grant Date Fair Value Per RSU Award Granted 2022 1,575,500 $ 104.99 2021 1,981,480 $ 81.91 Compensation expense related to RSU awards was as follows: Compensation Expense Related to RSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 $ 74 $ 35 2021 $ 73 $ 33 During the six months ended June 30, 2022 and 2021, shares granted to eligible employee and the grant date fair value per share related to PSU awards were as follows: Number of Shares Granted Grant Date Grant Date (Per Share) (Per Share) 2022 451,790 $ 105.07 $ 143.94 2021 574,410 $ 81.86 $ 106.93 Compensation expense related to PSU awards was as follows: Compensation Expense Related to PSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 $ 31 $ 10 2021 $ 46 $ 34
Schedule of assumptions used to determine the grant date fair value of the PSU awards subject to the TSR performance metric	The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance metric: 2022 2021 Risk-free interest rate (a) 1.6 % 0.2 % Expected volatility (b) 28.6 % 31.7 % (a) Based on the U.S. Treasury yield curve. (b) Determined using the observed historical volatility.

Benefit Plans (Tables)

Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Components of pension and other employee benefit costs	Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Net pension costs (income) $ (49) $ (2) $ (24) $ (1) Net postemployment costs 54 53 27 25 Net postretirement costs 4 4 2 3 Total pension and other employee benefit costs $ 9 $ 55 $ 5 $ 27
Components of net periodic benefit cost	Net periodic pension cost consisted of the following: Pension (1) For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Service cost $ 119 $ 147 $ 59 $ 72 Interest cost 38 25 18 12 Expected return on plan assets (180) (186) (88) (91) Amortization: Net loss 94 158 46 78 Prior service cost (1) 1 — — Net periodic pension cost $ 70 $ 145 $ 35 $ 71 (1) Primarily non-U.S. based defined benefit retirement plans.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of movements in goodwill	The movements in goodwill were as follows: (in millions) European Union Eastern Europe Middle East & Africa South & Southeast Asia East Asia & Australia Americas Wellness and Healthcare Total Balances, December 31, 2021 $ 1,397 $ 295 $ 79 $ 2,828 $ 539 $ 611 $ 931 $ 6,680 Changes due to: Currency (98) (17) (1) (141) (31) 8 (82) (362) Balances, June 30, 2022 $ 1,299 $ 278 $ 78 $ 2,687 $ 508 $ 619 $ 849 $ 6,318
Schedule of amortizable intangible assets	Details of other intangible assets were as follows: June 30, 2022 December 31, 2021 (in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Non-amortizable intangible assets $ 1,289 $ 1,289 $ 1,312 $ 1,312 Amortizable intangible assets: Trademarks 11 years 1,159 $ 647 512 1,201 $ 639 562 Developed technology, including patents 12 years 820 98 722 859 63 796 Other (1) 11 years 226 93 133 238 90 148 Total other intangible assets $ 3,494 $ 838 $ 2,656 $ 3,610 $ 792 $ 2,818 (1) Primarily includes distribution networks and customer relationships.
Schedule of non-amortizable intangible assets	Details of other intangible assets were as follows: June 30, 2022 December 31, 2021 (in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Non-amortizable intangible assets $ 1,289 $ 1,289 $ 1,312 $ 1,312 Amortizable intangible assets: Trademarks 11 years 1,159 $ 647 512 1,201 $ 639 562 Developed technology, including patents 12 years 820 98 722 859 63 796 Other (1) 11 years 226 93 133 238 90 148 Total other intangible assets $ 3,494 $ 838 $ 2,656 $ 3,610 $ 792 $ 2,818 (1) Primarily includes distribution networks and customer relationships.

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value of derivative contracts	The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, were as follows: Derivative Assets Derivative Liabilities Fair Value Fair Value At At At At (in millions) Balance Sheet Classification June 30, 2022 December 31, 2021 Balance Sheet Classification June 30, 2022 December 31, 2021 Derivative contracts designated as hedging instruments Other current assets $ 388 $ 173 Other accrued liabilities $ 8 $ 34 Other assets 297 22 Income taxes and other liabilities 75 190 Derivative contracts not designated as hedging instruments Other current assets 111 37 Other accrued liabilities 151 75 Other assets 4 — Income taxes and other liabilities 19 — Total gross amount derivatives contracts presented in the condensed consolidated balance sheets $ 800 $ 232 $ 253 $ 299 Gross amounts not offset in the condensed consolidated balance sheets Financial instruments (148) (126) (148) (126) Cash collateral received/pledged (636) (93) (68) (151) Net amount $ 16 $ 13 $ 37 $ 22
Derivative contracts impact on the condensed consolidated statements of earnings and other comprehensive earnings	For the six months ended June 30, 2022 and 2021, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Six Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2022 2021 2022 2021 2022 2021 Derivative contracts designated as hedging instruments: Cash flow hedges $ 355 $ 89 Net revenues $ 81 $ 17 Cost of sales — — Marketing, administration and research costs (10) (12) Interest expense, net (7) (7) Fair value hedges Interest expense, net $ (57) $ — Net investment hedges (a) 530 192 Interest expense, net (b) 68 82 Derivative contracts not designated as hedging instruments: Interest expense, net 43 25 Marketing, administration and research costs (c) 65 196 Total $ 885 $ 281 $ 64 $ (2) $ 119 $ 303 (a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar. (b) Represent the gains for amounts excluded from the effectiveness testing (c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are primarily offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged For the three months ended June 30, 2022 and 2021, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Three Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2022 2021 2022 2021 2022 2021 Derivative contracts designated as hedging instruments: Cash flow hedges $ 225 $ (1) Net revenues $ 64 $ 17 Cost of sales — — Marketing, administration and research costs (7) 6 Interest expense, net (4) (4) Fair value hedges Interest expense, net $ (20) $ — Net investment hedges (a) 425 (126) Interest expense, net (b) 35 40 Derivative contracts not designated as hedging instruments: Interest expense, net 35 14 Marketing, administration and research costs (c) 66 (91) Total $ 650 $ (127) $ 53 $ 19 $ 116 $ (37) (a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar (b) Represent the gains for amounts excluded from the effectiveness testing (c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are primarily offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged
Qualifying hedging activity reported in accumulated other comprehensive earnings (losses), net of income taxes	Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Gain/(loss) as of beginning of period $ 4 $ (85) $ 105 $ 12 Derivative (gains)/losses transferred to earnings (55) 2 (46) (19) Change in fair value 301 77 191 1 Gain/(loss) as of June 30, $ 250 $ (6) $ 250 $ (6)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Calculation of basic and diluted EPS	Basic and diluted earnings per share (“EPS”) were calculated using the following: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Net earnings attributable to PMI $ 4,564 $ 4,590 $ 2,233 $ 2,172 Less distributed and undistributed earnings attributable to share-based payment awards 13 14 7 6 Net earnings for basic and diluted EPS $ 4,551 $ 4,576 $ 2,226 $ 2,166 Weighted-average shares for basic EPS 1,550 1,558 1,551 1,558 Plus contingently issuable performance stock units (PSUs) 2 2 1 2 Weighted-average shares for diluted EPS 1,552 1,560 1,552 1,560

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment data	Segment data were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Net revenues: European Union $ 6,155 $ 6,058 $ 3,143 $ 3,149 Eastern Europe 1,624 1,691 898 895 Middle East & Africa 1,997 1,361 1,006 560 South & Southeast Asia 2,157 2,219 1,034 1,046 East Asia & Australia 2,610 2,986 1,206 1,514 Americas 893 864 469 430 Wellness and Healthcare 142 — 76 — Net revenues $ 15,578 $ 15,179 $ 7,832 $ 7,594 Operating income (loss): European Union $ 3,046 $ 3,131 $ 1,519 $ 1,641 Eastern Europe 435 575 291 314 Middle East & Africa 1,019 351 498 16 South & Southeast Asia 751 860 306 331 East Asia & Australia 917 1,410 346 715 Americas 251 246 130 112 Wellness and Healthcare (65) — (34) — Operating income $ 6,354 $ 6,573 $ 3,056 $ 3,129 PMI's net revenues by product category were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2022 2021 2022 2021 Net revenues: Combustible products: European Union $ 3,763 $ 4,113 $ 1,954 $ 2,162 Eastern Europe 1,042 1,047 585 555 Middle East & Africa 1,862 1,307 933 527 South & Southeast Asia 2,147 2,216 1,029 1,045 East Asia & Australia 1,129 1,259 528 611 Americas 876 840 460 418 Total combustible products $ 10,819 $ 10,781 $ 5,489 $ 5,318 Reduced-risk products: European Union $ 2,392 $ 1,945 $ 1,189 $ 987 Eastern Europe 582 644 313 340 Middle East & Africa 135 54 73 33 South & Southeast Asia 10 3 5 1 East Asia & Australia 1,481 1,727 678 903 Americas 17 24 9 12 Total reduced-risk products $ 4,617 $ 4,398 $ 2,267 $ 2,276 Wellness and Healthcare: Wellness and Healthcare $ 142 $ — $ 76 $ — Total PMI net revenues $ 15,578 $ 15,179 $ 7,832 $ 7,594

Contingencies (Tables)

Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of tobacco related cases pertaining to combustible products pending against company	The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as of June 30, 2022, and June 30, 2021:¹ Type of Case Number of Cases Pending as of June 30, 2022 Number of Cases Pending as of June 30, 2021 Individual Smoking and Health Cases 40 44 Smoking and Health Class Actions 9 9 Health Care Cost Recovery Actions 17 17 Label-Related Class Actions — — Individual Label-Related Cases 5 4 Public Civil Actions 1 2
Schedule of verdicts and significant post trial developments where a verdict was returned in favor of the plaintiff(s)	The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff: Date Location of Type of Verdict Post-Trial May 27, 2015 Canada/Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais Class Action On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Blais class on liability and found the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $12 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion including pre-judgment interest (approximately $2.4 billion)). The trial court awarded CAD 90,000 (approximately $69,700) in punitive damages, allocating CAD 30,000 (approximately $23,200) to our subsidiary. The trial court ordered defendants to pay CAD 1 billion (approximately $774 million) of the compensatory damage award, CAD 200 million (approximately $155 million) of which is our subsidiary’s portion, into a trust within 60 days. In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “ Stayed Litigation — Canada ” for further detail.) Date Location of Type of Verdict Post-Trial May 27, 2015 Canada/Cecilia Létourneau Class Action On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Létourneau class on liability and awarded a total of CAD 131 million (approximately $101 million) in punitive damages, allocating CAD 46 million (approximately $35.6 million) to RBH. The trial court ordered defendants to pay the full punitive damage award into a trust within 60 days. The court did not order the payment of compensatory damages. In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “ Stayed Litigation — Canada ” for further detail.) Date Location of Type of Verdict Post-Trial August 5, 2016 Argentina/Hugo Lespada Individual Action On August 5, 2016, the Civil Court No. 14 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded him ARS 110,000 (approximately $848), plus interest, in compensatory and moral damages. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes. On August 23, 2016, our subsidiary filed its notice of appeal. On October 31, 2017, the Civil and Commercial Court of Appeals of Mar del Plata ruled that plaintiff's claim was barred by the statute of limitations and it reversed the trial court's decision. On May 17, 2021 plaintiff filed a federal extraordinary appeal. On November 1, 2021, the Supreme Court of the Province of Buenos Aires dismissed plaintiff's federal extraordinary appeal. On November 10, 2021, plaintiff filed a direct appeal before the Federal Supreme Court. Date Location of Type of Verdict Post-Trial June 17, 2021 Argentina/Claudia Milano Individual Action On June 17, 2021, the Civil Court No. 9 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded her smoking cessation treatments, ARS 150,000 (approximately $1,157), in compensatory and moral damages, and ARS 4,000,000 (approximately $30,848) in punitive damages, plus interest and costs. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes. On July 2, 2021, our subsidiary filed its notice of appeal. In addition, plaintiff filed an appeal challenging the dismissal of the claim for psychological damages. As required by local law, our subsidiary deposited the damages awarded, plus interest and costs, in total ARS 6,114,428 (approximately $47,154), into a court escrow account. Our subsidiary challenged the amount determined by the court. The Civil and Commercial Court of Appeals of Mar del Plata granted our subsidiary's challenge to the escrow amount determined by the trial court. As a result, on December 16, 2021, ARS 893,428 (approximately $6,890) was returned to our subsidiary. If our subsidiary ultimately prevails, the remaining deposited amounts will be returned to our subsidiary. On May 31, 2022, the Civil and Commercial Court of Appeals of Mar del Plata ruled that the statute of limitations barred plaintiff's claim and reversed the trial court's decision. On June 15, 2022, plaintiff filed an extraordinary appeal.

Indebtedness (Tables)

Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-term debt	At June 30, 2022 and December 31, 2021, PMI’s long-term debt consisted of the following: (in millions) June 30, 2022 December 31, 2021 U.S. dollar notes, 0.875% to 6.375% (average interest rate 3.261%), due through 2044 $ 18,853 $ 19,397 Foreign currency obligations: Euro notes, 0.125% to 3.125% (average interest rate 1.995%), due through 2039 7,149 7,687 Swiss franc note, 1.625%, due 2024 263 273 Other (average interest rate 3.496%), due through 2029 (a) 229 224 Carrying value of long-term debt 26,494 27,581 Less current portion of long-term debt 4,149 2,798 $ 22,345 $ 24,783
Aggregate fair values of PMI's debt, excluding finance leases	At June 30, 2022, the fair value of PMI's outstanding long-term debt, excluding the aforementioned finance leases, was as follows: (in millions) June 30, 2022 Level 1 $ 23,930 Level 2 153
Schedule of committed credit facilities	At June 30, 2022, PMI's total committed revolving credit facilities were as follows: (in billions) Type Committed 364-day revolving credit, expiring January 31, 2023 1.8 Multi-year revolving credit, expiring February 10, 2026 (1) 2.0 Multi-year revolving credit, expiring September 29, 2026 (2) 2.5 Total facilities $ 6.3 (1) On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion. (2) Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails to achieve, certain specified targets.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Losses (Tables)	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Components of accumulated other comprehensive earnings (losses), net of taxes	PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following: (Losses) Earnings At At At (in millions) June 30, 2022 December 31, 2021 June 30, 2021 Currency translation adjustments $ (6,558) $ (6,701) $ (6,586) Pension and other benefits (2,735) (2,880) (4,073) Derivatives accounted for as hedges 250 4 (6) Total accumulated other comprehensive losses $ (9,043) $ (9,577) $ (10,665)

Related Parties - Equity Inve_2

Related Parties - Equity Investments and Other (Tables)	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Earnings and balance sheet activities with related parties - equity investments and other	PMI’s net revenues and expenses with the above related parties were as follows: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Net revenues: Megapolis Group $ 993 $ 1,038 $ 606 $ 555 Other 554 560 263 280 Net revenues (a) $ 1,547 $ 1,598 $ 869 $ 835 Expenses: Other $ 29 $ 33 $ 17 $ 16 Expenses $ 29 $ 33 $ 17 $ 16 (a) Net revenues exclude excise taxes and VAT billed to customers. PMI’s balance sheet activity with the above related parties was as follows: (in millions) At June 30, 2022 At December 31, 2021 Receivables: Megapolis Group $ 725 $ 319 Other 243 199 Receivables $ 968 $ 518 Payables: Other $ 32 $ 25 Payables $ 32 $ 25

Product Warranty (Tables)

Product Warranty (Tables)	6 Months Ended
	Jun. 30, 2022
Guarantees and Product Warranties [Abstract]
Schedule of accrued product warranties	At June 30, 2022 and December 31, 2021, these amounts were as follows: (in millions) As of and For the Six Months Ended June 30, 2022 As of and For the Year Ended December 31, 2021 Balance at beginning of period $ 113 $ 137 Changes due to: Warranties issued 67 154 Settlements (60) (177) Currency/Other 2 (1) Balance at end of period $ 122 $ 113

Asset Impairment and Exit Cos_2

Asset Impairment and Exit Costs (Tables)	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Pre-tax asset impairment and exit costs by segment	PMI recorded the following pre-tax asset impairment and exit costs by segment: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2021 2021 Separation programs: (1) European Union $ 44 $ 35 Eastern Europe 9 7 Middle East & Africa 10 8 South & Southeast Asia 13 10 East Asia & Australia 20 15 Americas 5 4 Total separation programs 101 79 Contract termination charges: East Asia & Australia 26 — Total contract termination charges 26 — Asset impairment and exit costs $ 127 $ 79 (1) Organizational design optimization pre-tax charges in 2021 were allocated across all geographical segments.
Movement in exit cost liabilities	The movement in exit cost liabilities for the six months ended June 30, 2022 was as follows: (in millions) Liability balance, January 1, 2022 $ 142 Charges, net — Cash spent (47) Currency/other (5) Liability balance, June 30, 2022 $ 90

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lease cost components	The components of PMI’s lease cost were as follows for the six months and three months ended June 30, 2022 and 2021: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2022 2021 2022 2021 Operating lease cost $ 126 $ 126 $ 64 $ 66 Finance lease cost: Amortization of right-of-use assets 47 17 31 9 Short-term lease cost 30 25 16 15 Variable lease cost 11 14 5 7 Total lease cost $ 214 $ 182 $ 116 $ 97

Acquisitions (Details)

Acquisitions (Details) £ / shares in Units, $ in Millions, £ in Billions, kr in Billions						3 Months Ended		6 Months Ended
	Sep. 15, 2021 USD ($)	Sep. 15, 2021 DKK (kr)	Sep. 15, 2021 GBP (£)	Aug. 09, 2021 USD ($)	May 06, 2021 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jan. 05, 2022	Dec. 31, 2021 USD ($)	Sep. 15, 2021 £ / shares
Business Acquisition [Line Items]
Other								$ 211
Goodwill								$ 6,318		$ 6,680
OtiTopic Inc Asset Acquisition
Business Acquisition [Line Items]
Asset acquisition, percentage of shares acquired				100%
Asset acquisition, consideration transferred				$ 38
Asset acquisition, contingent payment				13
Asset acquisition, future additional contingent payments				$ 25
Pre-tax charge associated with asset acquisition							$ 51
Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş.
Business Acquisition [Line Items]
Percentage of voting interests acquired									25%
Philip Morris Pazarlama ve Satış A.Ş.
Business Acquisition [Line Items]
Percentage of voting interests acquired									24.75%
Turkish Affiliates Acquisitions
Business Acquisition [Line Items]
Payments to acquire additional interest in subsidiaries						$ 223
Percentage of voting interest held following additional purchases of shares (as a percent)						100%
Increase (decrease) in additional paid in capital from business combinations						$ 30
Other						$ 171
AG Snus
Business Acquisition [Line Items]
Percentage of voting interests acquired					100%
Cash payment for business, net of cash acquired					$ 28
Additional contingent payments					$ 10
Contingent payment target period					2 years
Fertin Pharma
Business Acquisition [Line Items]
Percentage of voting interests acquired	100%
Total consideration transferred	$ 821	kr 5.2
Cash payment for business combination	821
Cash	24
Current assets	69
Property, plant and equipment	228
Goodwill	378
Other intangible assets	245
Current liabilities	44
Noncurrent liabilities	79
Fertin Pharma | Cash Consideration
Business Acquisition [Line Items]
Total consideration transferred	580
Fertin Pharma | Consideration For Payment To Settle Indebtedness
Business Acquisition [Line Items]
Total consideration transferred	$ 241
Fertin Pharma | Minimum
Business Acquisition [Line Items]
Acquired intangible assets, estimated useful life	8 years	8 years	8 years
Fertin Pharma | Maximum
Business Acquisition [Line Items]
Acquired intangible assets, estimated useful life	19 years	19 years	19 years
Vectura
Business Acquisition [Line Items]
Percentage of voting interests acquired	74.77%
Percentage of voting interest held following additional purchases of shares (as a percent)										100%
Total consideration transferred	$ 1,384		£ 1
Cash	136
Current assets	89
Property, plant and equipment	67
Goodwill	590
Other intangible assets	719
Current liabilities	100
Noncurrent liabilities	$ 117
Business acquisition, share price (in dollars per share) | £ / shares											£ 165
Vectura | Minimum
Business Acquisition [Line Items]
Acquired intangible assets, estimated useful life	3 years	3 years	3 years
Vectura | Maximum
Business Acquisition [Line Items]
Acquired intangible assets, estimated useful life	15 years	15 years	15 years

War in Ukraine (Details)

War in Ukraine (Details) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022 USD ($) employee	Jun. 30, 2022 USD ($) employee	Dec. 31, 2021 USD ($)
Unusual or Infrequent Item, or Both [Line Items]
Total assets	$ 40,960	$ 40,960	$ 41,290
Inventories	7,551	7,551	8,720
Goodwill (Note 6)	6,318	6,318	$ 6,680
War In Ukraine
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	80	122
War In Ukraine | Cost of sales
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	20	46
War In Ukraine | Marketing, administration and research costs
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	$ 60	$ 76
Ukraine
Unusual or Infrequent Item, or Both [Line Items]
Number of employees | employee	1,300	1,300
Ukraine | War In Ukraine
Unusual or Infrequent Item, or Both [Line Items]
Total assets	$ 456	$ 456
Receivables	70	70
Inventories	304	304
Property, plant and equipment	41	41
Pre-tax charge related to conflict in Ukraine	24	51
Ukraine | War In Ukraine | Cost of sales
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	14	25
Ukraine | War In Ukraine | Marketing, administration and research costs
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	10	26
Russia | War In Ukraine
Unusual or Infrequent Item, or Both [Line Items]
Total assets	2,500	2,500
Receivables	730	730
Inventories	679	679
Property, plant and equipment	501	501
Goodwill (Note 6)	161	161
Cumulative foreign currency translation losses	317	317
Pre-tax charge related to conflict in Ukraine	56	71
Russia | War In Ukraine | Cost of sales
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	6	21
Russia | War In Ukraine | Marketing, administration and research costs
Unusual or Infrequent Item, or Both [Line Items]
Pre-tax charge related to conflict in Ukraine	$ 50	$ 50

Stock Plans (Additional Informa

Stock Plans (Additional Information) (Details) - shares	Jun. 30, 2022	May 31, 2022	May 31, 2017
Non Employee Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated common stock to be awarded under a stock benefit plan, maximum limit (in shares)			1,000,000
Shares available for grant under the plan (in shares)	894,346
Percentage of voting shares that PMI may own, used in determining non-employee director status			50%
2022 Performance Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated common stock to be awarded under a stock benefit plan, maximum limit (in shares)		25,000,000
Shares available for grant under the plan (in shares)	24,980,480

Stock Plans (RSU Awards) (Detai

Stock Plans (RSU Awards) (Details) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) year $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense Related to RSU Awards	$ 10	$ 34	$ 31	$ 46
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Granted (in shares) | shares			1,575,500	1,981,480
Weighted-Average Grant Date Fair Value Per RSU Award Granted (in dollars per share) | $ / shares			$ 104.99	$ 81.91
Compensation Expense Related to RSU Awards	35	$ 33	$ 74	$ 73
Unrecognized compensation cost related to non-vested stock awards	$ 224		$ 224
Award requisite service period			3 years
Minimum retirement age | year			58
Stock awards vested during period (in shares) | shares			1,508,880
Restricted Stock Units (RSUs) | Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards			$ 118
Restricted Stock Units (RSUs) | Total Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards			$ 165

Stock Plans (PSU Awards) (Detai

Stock Plans (PSU Awards) (Details) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) performanceMetric year $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense Related to PSU Awards	$ 10	$ 34	$ 31	$ 46
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Length of performance cycle period			3 years
Absolute basis (as a percent)	40%	40%	40%	40%
Currency-neutral compound annual adjusted diluted earnings per share growth rate (as a percent)	30%	30%	30%	30%
Product sustainability weight (as a percent)	20%		20%
Operational sustainability weight (as a percentage)	10%		10%
Performance against specific measures of transformation (as a percent)		30%		30%
Performance metrics predefined at time of grant | performanceMetric			3
Aggregate weighted performance factor			100%
Number of shares of common stock issued for each vested PSU (in shares) | shares			1
Number of Shares Granted (in shares) | shares			451,790	574,410
Risk-free interest rate (as a percent)			1.60%	0.20%
Expected volatility (as a percent)			28.60%	31.70%
Unrecognized compensation cost related to non-vested stock awards	$ 67		$ 67
Minimum retirement age | year			58
Stock awards vested during period (in shares) | shares			669,960
Performance Shares | Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards			$ 54
Performance Shares | Total Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards			$ 74
Performance Shares | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage			0%
Performance Shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage			200%
Performance Share Units, Other Performance Metrics
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-Average Grant Date Fair Value Per RSU Award Granted (in dollars per share) | $ / shares			$ 105.07	$ 81.86
Performance Share Units, TSR Performance Metric
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-Average Grant Date Fair Value Per RSU Award Granted (in dollars per share) | $ / shares			$ 143.94	$ 106.93

Benefit Plans (Components of Pe

Benefit Plans (Components of Pension and Other Employee Benefits Costs) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	$ 5	$ 27	$ 9	$ 55
Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	(24)	(1)	(49)	(2)
Postemployment Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	27	25	54	53
Postretirement Benefit Costs
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	$ 2	$ 3	$ 4	$ 4

Benefit Plans (Components of Ne

Benefit Plans (Components of Net Periodic Benefit Cost) (Details) - Pension Plan - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 59	$ 72	$ 119	$ 147
Interest cost	18	12	38	25
Expected return on plan assets	(88)	(91)	(180)	(186)
Amortization:
Net loss	46	78	94	158
Prior service cost	0	0	(1)	1
Net periodic pension cost	$ 35	$ 71	$ 70	$ 145

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Retirement Benefits [Abstract]
Employer contributions		$ 60
Received a cash refund	$ 123
Anticipated additional employer contributions during the remainder of the current fiscal year	$ 53	$ 53

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, net (Movement in Goodwill) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Roll Forward]
Beginning Balance	$ 6,680
Changes due to:
Currency	(362)
Ending Balance	6,318
European Union
Goodwill [Roll Forward]
Beginning Balance	1,397
Changes due to:
Currency	(98)
Ending Balance	1,299
Eastern Europe
Goodwill [Roll Forward]
Beginning Balance	295
Changes due to:
Currency	(17)
Ending Balance	278
Middle East & Africa
Goodwill [Roll Forward]
Beginning Balance	79
Changes due to:
Currency	(1)
Ending Balance	78
South & Southeast Asia
Goodwill [Roll Forward]
Beginning Balance	2,828
Changes due to:
Currency	(141)
Ending Balance	2,687
East Asia & Australia
Goodwill [Roll Forward]
Beginning Balance	539
Changes due to:
Currency	(31)
Ending Balance	508
Americas
Goodwill [Roll Forward]
Beginning Balance	611
Changes due to:
Currency	8
Ending Balance	619
Wellness and Healthcare
Goodwill [Roll Forward]
Beginning Balance	931
Changes due to:
Currency	(82)
Ending Balance	$ 849

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, net (Additional Information) (Details) - USD ($)		3 Months Ended		6 Months Ended
	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Non-amortizable intangible assets, currency movements increase (decrease)				$ (23,000,000)
Finite lived intangible asset, currency movements increase (decrease)				94,000,000
Amortization of intangibles		$ 36,000,000	$ 19,000,000	74,000,000	$ 37,000,000
Change in accumulated amortization, currency movements				28,000,000
Estimated amortization expense, year one, assuming no additional transactions occur that require the amortization of intangible assets		145,000,000		145,000,000
Estimated amortization expense, year two, assuming no additional transactions occur that require the amortization of intangible assets		145,000,000		145,000,000
Estimated amortization expense, year three, assuming no additional transactions occur that require the amortization of intangible assets		145,000,000		145,000,000
Estimated amortization expense, year four, assuming no additional transactions occur that require the amortization of intangible assets		145,000,000		145,000,000
Estimated amortization expense, year five, assuming no additional transactions occur that require the amortization of intangible assets		145,000,000		$ 145,000,000
Impairment charges		$ 0
Wellness and Healthcare
Finite-Lived Intangible Assets [Line Items]
Excess of fair value over carrying value (as a percent)		20%		20%
European Union
Finite-Lived Intangible Assets [Line Items]
Goodwill transferred between segments	$ 24,000,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, net (Other Intangible Assets) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Non-amortizable intangible assets	$ 1,289	$ 1,312
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, Accumulated Amortization	838	792
Total other intangible assets, gross	3,494	3,610
Total other intangible assets, net	2,656	2,818
Finite lived intangible asset, currency movements increase (decrease)	$ (94)
Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	11 years
Amortizable intangible assets, Gross Carrying Amount	$ 1,159	1,201
Amortizable intangible assets, Accumulated Amortization	647	639
Amortizable intangible assets, Net	$ 512	562
Developed technology, including patents
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	12 years
Amortizable intangible assets, Gross Carrying Amount	$ 820	859
Amortizable intangible assets, Accumulated Amortization	98	63
Amortizable intangible assets, Net	$ 722	796
Other
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	11 years
Amortizable intangible assets, Gross Carrying Amount	$ 226	238
Amortizable intangible assets, Accumulated Amortization	93	90
Amortizable intangible assets, Net	$ 133	$ 148

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Derivative [Line Items]
Cumulative fair value gain (loss) of hedged liability	$ 56		$ 56
Level 1 | Other Investments
Derivative [Line Items]
Other investments	94		94
Net Investment Hedging | Foreign Debt
Derivative [Line Items]
Foreign currency gain (loss)	192	$ (71)	258	$ 110
Fair Value Hedging
Derivative [Line Items]
Fair value hedge amount	938		938
Derivative Contract
Derivative [Line Items]
Notional amount	29,100		29,100
Derivative instruments, gains (losses) to be reclassified to earnings	141		$ 141
Derivative Contract | Maximum
Derivative [Line Items]
Maximum length of time hedged in a cash flow hedge			18 months
Derivative Contract | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional amount	16,400		$ 16,400
Derivative Contract | Cash Flow Hedging
Derivative [Line Items]
Notional amount	5,000		5,000
Derivative Contract | Net Investment Hedging
Derivative [Line Items]
Notional amount	6,700		6,700
Derivative Contract | Fair Value Hedging
Derivative [Line Items]
Notional amount	$ 1,000		$ 1,000

Financial Instruments (Fair Val

Financial Instruments (Fair Value of Derivative Contracts) (Details) - Derivative Contract - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Derivative asset fair value	$ 800	$ 232
Gross amounts not offset in the condensed consolidated balance sheets - financial instruments	(148)	(126)
Gross amounts not offset in the condensed consolidated balance sheets - cash collateral received / pledged	(636)	(93)
Net amount	16	13
Derivative liability fair value	253	299
Gross amounts not offset in the condensed consolidated balance sheets - financial instruments	(148)	(126)
Gross amounts not offset in the condensed consolidated balance sheets - cash collateral received / pledged	(68)	(151)
Net amount	37	22
Derivative contracts designated as hedging instruments | Other Current Assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	388	173
Derivative contracts designated as hedging instruments | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	297	22
Derivative contracts designated as hedging instruments | Other accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	8	34
Derivative contracts designated as hedging instruments | Income taxes and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	75	190
Not Designated as Hedging Instrument | Other Current Assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	111	37
Not Designated as Hedging Instrument | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	4	0
Not Designated as Hedging Instrument | Other accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	151	75
Not Designated as Hedging Instrument | Income taxes and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	$ 19	$ 0

Financial Instruments (Cash Flo

Financial Instruments (Cash Flow and Net Investment Hedging Activities Effect on Condensed Consolidated Statements of Earnings and Other Comprehensive Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Derivative Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivative contracts designated as hedging instruments	$ 225	$ (1)	$ 355	$ 89
Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives in Net Investment Hedging Relationship	425	(126)	530	192
Total Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives	650	(127)	885	281
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	53	19	64	(2)
Derivative Contract | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	116	(37)	119	303
Derivative Contract | Net revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	64	17	81	17
Derivative Contract | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	0	0	0	0
Derivative Contract | Marketing, administration and research costs
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	(7)	6	(10)	(12)
Derivative Contract | Marketing, administration and research costs | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	66	(91)	65	196
Derivative Contract | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	(4)	(4)	(7)	(7)
Derivative Contract | Interest expense, net | Derivative contracts designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	35	40	68	82
Derivative Contract | Interest expense, net | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	35	14	43	25
Interest Rate Contract | Interest expense, net | Derivative contracts designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	$ (20)	$ 0	$ (57)	$ 0

Financial Instruments (Qualifyi

Financial Instruments (Qualifying Hedging Activity Reported in Accumulated Other Comprehensive Earnings (Losses) Net of Income Taxes) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ (8,203)	$ (9,574)	$ (8,208)	$ (10,631)
Ending balance	(7,260)	(9,200)	(7,260)	(9,200)
Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	105	12	4	(85)
Derivative (gains)/losses transferred to earnings	(46)	(19)	(55)	2
Change in fair value	191	1	301	77
Ending balance	$ 250	$ (6)	$ 250	$ (6)

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net earnings attributable to PMI	$ 2,233	$ 2,172	$ 4,564	$ 4,590
Less distributed and undistributed earnings attributable to share-based payment awards	7	6	13	14
Net earnings for basic EPS	2,226	2,166	4,551	4,576
Net earnings for diluted EPS	$ 2,226	$ 2,166	$ 4,551	$ 4,576
Weighted-average shares for basic EPS (in shares)	1,551,000,000	1,558,000,000	1,550,000,000	1,558,000,000
Plus contingently issuable performance stock units (PSUs) (in shares)	1,000,000	2,000,000	2,000,000	2,000,000
Weighted-average shares for diluted EPS (in shares)	1,552,000,000	1,560,000,000	1,552,000,000	1,560,000,000
Antidilutive stock awards (in shares)			0	0

Segment Reporting (Details)

Segment Reporting (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			6
Total PMI net revenues	$ 7,832	$ 7,594	$ 15,578	$ 15,179
Operating income	3,056	3,129	6,354	6,573
Incurred cost		79		127
Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	7,832	7,594	15,578	15,179
Operating income	3,056	3,129	6,354	6,573
European Union | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	3,143	3,149	6,155	6,058
Operating income	1,519	1,641	3,046	3,131
Eastern Europe
Segment Reporting Information [Line Items]
Pre-tax charge related to conflict in Ukraine	80		122
Eastern Europe | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	898	895	1,624	1,691
Operating income	291	314	435	575
Middle East & Africa | SAUDI ARABIA
Segment Reporting Information [Line Items]
Total PMI net revenues				246
Middle East & Africa | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	1,006	560	1,997	1,361
Operating income	498	16	1,019	351
South & Southeast Asia | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	1,034	1,046	2,157	2,219
Operating income	306	331	751	860
East Asia & Australia | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	1,206	1,514	2,610	2,986
Operating income	346	715	917	1,410
Americas | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	469	430	893	864
Operating income	130	112	251	246
Wellness and Healthcare | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	76	0	142	0
Operating income	(34)	0	(65)	0
Combustible Products | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	5,489	5,318	10,819	10,781
Combustible Products | European Union | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	1,954	2,162	3,763	4,113
Combustible Products | Eastern Europe | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	585	555	1,042	1,047
Combustible Products | Middle East & Africa | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	933	527	1,862	1,307
Combustible Products | South & Southeast Asia | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	1,029	1,045	2,147	2,216
Combustible Products | East Asia & Australia | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	528	611	1,129	1,259
Combustible Products | Americas | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	460	418	876	840
Reduced-Risk Products | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	2,267	2,276	4,617	4,398
Reduced-Risk Products | European Union | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	1,189	987	2,392	1,945
Reduced-Risk Products | Eastern Europe | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	313	340	582	644
Reduced-Risk Products | Middle East & Africa | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	73	33	135	54
Reduced-Risk Products | South & Southeast Asia | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	5	1	10	3
Reduced-Risk Products | East Asia & Australia | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	678	903	1,481	1,727
Reduced-Risk Products | Americas | Operating Segments
Segment Reporting Information [Line Items]
Total PMI net revenues	$ 9	$ 12	$ 17	$ 24

Contingencies (Tobacco-Related

Contingencies (Tobacco-Related Litigation) (Details)							1 Months Ended		3 Months Ended
	Mar. 01, 2019 CAD ($)	Mar. 01, 2019 USD ($)	May 27, 2015 CAD ($) plaintiff manufacturer	May 27, 2015 USD ($) plaintiff manufacturer	Jun. 20, 2012 cigarette	Jul. 10, 2009 cigarette	Oct. 30, 2015 CAD ($)	Oct. 30, 2015 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2022 litigationCase
Loss Contingencies [Line Items]
Number of cases decided in favor of PM										526
Number of cases decided in favor of plaintiff										14
Cases Remaining On Appeal
Loss Contingencies [Line Items]
Cases on appeal										4
Case Decided In Favor Of Plaintiff
Loss Contingencies [Line Items]
Number of cases that reached final resolution in favor of PM										10
Canada | Adams | Pending Litigation
Loss Contingencies [Line Items]
Minimum number of cigarettes smoked | cigarette						25,000
Canada | Suzanne Jacklin | Pending Litigation
Loss Contingencies [Line Items]
Minimum number of cigarettes smoked | cigarette					25,000
Canada | Smoking and Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais
Loss Contingencies [Line Items]
Number of additional manufacturers found liable | manufacturer			2	2
Court-estimated number of members in class | plaintiff			99,957	99,957
Canada | Smoking and Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais | Judicial Ruling | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Compensatory damages awarded			$ 15,500,000,000	$ 12,000,000,000
Punitive damages awarded			90,000	69,700
Damages, reduced amount	$ 13,500,000,000	$ 10,500,000,000
Canada | Smoking and Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais | Judicial Ruling | RBH
Loss Contingencies [Line Items]
Compensatory damages awarded	$ 2,700,000,000	$ 2,100,000,000	$ 3,100,000,000	$ 2,400,000,000
Damages allocated to subsidiary (percent)	20%	20%	20%	20%
Punitive damages awarded			$ 30,000	$ 23,200
Canada | Smoking and Health Class Actions | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases | Judicial Ruling | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Amount to be deposited into trust	$ 1,100,000,000	$ 852,000,000
Payment period	60 days	60 days
Canada | Smoking and Health Class Actions | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases | Appellate Ruling | RBH
Loss Contingencies [Line Items]
Motion for security ordered by appeals court, paid by defendant							$ 226,000,000	$ 175,000,000
Amount of security ordered, funded by defendant	$ 257,000,000	$ 194,000,000
Amount of litigation charge | $									$ 194,000,000
Amount of litigation charge net of tax | $									$ 142,000,000
Canada | Smoking and Health Class Actions | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases | Appellate Ruling | Imperial Tobacco Ltd.
Loss Contingencies [Line Items]
Motion for security ordered by appeals court							$ 758,000,000	$ 586,000,000
Canada | Smoking and Health Class Actions | Cecilia Letourneau
Loss Contingencies [Line Items]
Number of additional manufacturers found liable | manufacturer			2	2
Court-estimated number of members in class | plaintiff			918,000	918,000
Canada | Smoking and Health Class Actions | Cecilia Letourneau | Judicial Ruling | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Punitive damages awarded			$ 131,000,000	$ 101,000,000
Canada | Smoking and Health Class Actions | Cecilia Letourneau | Judicial Ruling | RBH
Loss Contingencies [Line Items]
Punitive damages awarded			$ 46,000,000	$ 35,600,000
Punitive damages, value	$ 57,000,000	$ 44,000,000

Contingencies (Number of Tobacc

Contingencies (Number of Tobacco Related Cases Pertaining to Combustible Products Pending Against Us and/or Our Subsidiaries or Indemnitees) (Details) - Combustible Products - litigationCase	Jun. 30, 2022	Jun. 30, 2021
Individual Smoking and Health Cases
Loss Contingencies [Line Items]
Cases brought against PM	40	44
Smoking and Health Class Actions
Loss Contingencies [Line Items]
Cases brought against PM	9	9
Health Care Cost Recovery Actions
Loss Contingencies [Line Items]
Cases brought against PM	17	17
Label-Related Class Actions
Loss Contingencies [Line Items]
Cases brought against PM	0	0
Individual Label-Related Cases
Loss Contingencies [Line Items]
Cases brought against PM	5	4
Public Civil Actions
Loss Contingencies [Line Items]
Cases brought against PM	1	2

Contingencies (Verdicts and Pos

Contingencies (Verdicts and Post-Trial Developments) (Details) - Judicial Ruling	Dec. 16, 2021 USD ($)	Dec. 16, 2021 ARS ($)	Jul. 02, 2021 USD ($)	Jul. 02, 2021 ARS ($)	Jun. 17, 2021 USD ($)	Jun. 17, 2021 ARS ($)	Mar. 01, 2019 CAD ($)	Mar. 01, 2019 USD ($)	Aug. 05, 2016 USD ($)	Aug. 05, 2016 ARS ($)	May 27, 2015 CAD ($)	May 27, 2015 USD ($)
Canada | Smoking and Health Class Actions | Cecilia Letourneau | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Punitive damages awarded											$ 131,000,000	$ 101,000,000
Canada | Smoking and Health Class Actions | Cecilia Letourneau | RBH
Loss Contingencies [Line Items]
Punitive damages awarded											$ 46,000,000	$ 35,600,000
Payment period for awarded punitive damages to be deposited into trust											60 days	60 days
Canada | Smoking and Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Compensatory damages awarded											$ 15,500,000,000	$ 12,000,000,000
Punitive damages awarded											90,000	69,700
Awarded compensatory damages that are to be deposited into trust											1,000,000,000	774,000,000
Canada | Smoking and Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais | RBH
Loss Contingencies [Line Items]
Compensatory damages awarded							$ 2,700,000,000	$ 2,100,000,000			$ 3,100,000,000	$ 2,400,000,000
Damages allocated to subsidiary (percent)							20%	20%			20%	20%
Punitive damages awarded											$ 30,000	$ 23,200
Awarded compensatory damages that are to be deposited into trust											$ 200,000,000	$ 155,000,000
Payment period for compensatory damages to be deposited into trust											60 days	60 days
Argentina | Individual Action | Hugo Lespada
Loss Contingencies [Line Items]
Compensatory damages awarded									$ 848	$ 110,000
Argentina | Individual Action | Claudia Milano
Loss Contingencies [Line Items]
Compensatory damages awarded					$ 1,157	$ 150,000
Punitive damages awarded					$ 30,848	$ 4,000,000
Amount to be deposited into trust			$ 47,154	$ 6,114,428
Damages returned to subsidiary	$ 6,890	$ 893,428

Contingencies (Smoking and Heal

Contingencies (Smoking and Health Litigation) (Details) - Combustible Products - litigationCase	Jun. 30, 2022	Jun. 30, 2021
Individual Smoking and Health Cases
Loss Contingencies [Line Items]
Cases brought against PM	40	44
Individual Smoking and Health Cases | Argentina
Loss Contingencies [Line Items]
Cases brought against PM	31
Individual Smoking and Health Cases | Brazil
Loss Contingencies [Line Items]
Cases brought against PM	1
Individual Smoking and Health Cases | Canada
Loss Contingencies [Line Items]
Cases brought against PM	2
Individual Smoking and Health Cases | Chile
Loss Contingencies [Line Items]
Cases brought against PM	2
Individual Smoking and Health Cases | Philippines
Loss Contingencies [Line Items]
Cases brought against PM	1
Individual Smoking and Health Cases | Turkey
Loss Contingencies [Line Items]
Cases brought against PM	1
Individual Smoking and Health Cases | Scotland
Loss Contingencies [Line Items]
Cases brought against PM	1
Individual Smoking and Health Cases | United States
Loss Contingencies [Line Items]
Cases brought against PM	1
Smoking and Health Class Actions
Loss Contingencies [Line Items]
Cases brought against PM	9	9

Contingencies (Health Care Cost

Contingencies (Health Care Cost Recovery Litigation) (Details) - Health Care Cost Recovery Actions	Apr. 14, 2014 patient	Oct. 17, 2008	Mar. 13, 2008	Feb. 26, 2008	May 25, 2007	May 09, 2007	Jun. 30, 2022 litigationCase	Jun. 30, 2021 litigationCase
Korea
Loss Contingencies [Line Items]
Damages sought, number of patients | patient	3,484
Nigeria | Pending Litigation | The Attorney General Of Lagos State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements			20 years
Damages sought, period of future reimbursements			20 years
Nigeria | Pending Litigation | The Attorney General Of Kano State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements						20 years
Damages sought, period of future reimbursements						20 years
Nigeria | Pending Litigation | The Attorney General Of Gombe State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements		20 years
Damages sought, period of future reimbursements		20 years
Nigeria | Pending Litigation | The Attorney General Of Oyo State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements					20 years
Damages sought, period of future reimbursements					20 years
Nigeria | Pending Litigation | The Attorney General Of Ogun State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements				20 years
Damages sought, period of future reimbursements				20 years
Combustible Products
Loss Contingencies [Line Items]
Cases brought against PM							17	17
Combustible Products | Brazil
Loss Contingencies [Line Items]
Cases brought against PM							1
Combustible Products | Canada
Loss Contingencies [Line Items]
Cases brought against PM							10
Combustible Products | Korea
Loss Contingencies [Line Items]
Cases brought against PM							1
Combustible Products | Nigeria
Loss Contingencies [Line Items]
Cases brought against PM							5

Contingencies (Label-Related Ca

Contingencies (Label-Related Cases) (Details) - Individual Label-Related Cases - Combustible Products - litigationCase	Jun. 30, 2022	Jun. 30, 2021
Loss Contingencies [Line Items]
Cases brought against PM	5	4
Italy
Loss Contingencies [Line Items]
Cases brought against PM	1
Chile
Loss Contingencies [Line Items]
Cases brought against PM	4

Contingencies (Public Civil Act

Contingencies (Public Civil Actions) (Details) - Public Civil Actions - Combustible Products - litigationCase	Jun. 30, 2022	Jun. 30, 2021
Loss Contingencies [Line Items]
Cases brought against PM	1	2
Venezuela
Loss Contingencies [Line Items]
Cases brought against PM	1

Contingencies (Other Litigation

Contingencies (Other Litigation) (Details) ฿ in Millions, $ in Millions, ₩ in Billions, ر.س in Billions

1 Months Ended

3 Months Ended

5 Months Ended

6 Months Ended

12 Months Ended

Jun. 15, 2022 USD ($)

Jun. 01, 2022 USD ($)

Jun. 01, 2022 THB (฿)

Jan. 26, 2017 USD ($)

Jan. 26, 2017 THB (฿)

Jan. 18, 2016 USD ($) defendant

Jan. 18, 2016 THB (฿) defendant

Jun. 30, 2020 USD ($)

Jun. 30, 2020 KRW (₩)

Mar. 31, 2020 USD ($)

Mar. 31, 2020 THB (฿)

Jan. 31, 2020 USD ($)

Jan. 31, 2020 KRW (₩)

Nov. 30, 2019 USD ($)

Nov. 30, 2019 THB (฿)

Jun. 30, 2022 USD ($)

Jun. 30, 2021 USD ($)

Mar. 31, 2017 USD ($)

Mar. 31, 2017 KRW (₩)

Mar. 31, 2017 USD ($)

Mar. 31, 2017 KRW (₩)

Jun. 30, 2022 USD ($)

Jun. 30, 2021 USD ($)

Dec. 31, 2016 USD ($)

Dec. 31, 2016 KRW (₩)

Jun. 30, 2022 SAR (ر.س)

Loss Contingencies [Line Items]

Total PMI net revenues

$ 7,832

$ 7,594

$ 15,578

$ 15,179

Other Litigation

Loss Contingencies [Line Items]

Damages awarded

$ 10.8

Thailand | Other Litigation | The Department of Special Investigations of the Government of Thailand

Loss Contingencies [Line Items]

Loss contingency, damages sought, value

$ 3.3

฿ 122

$ 539

฿ 19,800

$ 2,200

฿ 80,800

$ 3.5

฿ 130

$ 33

฿ 1,200

Korea | Other Litigation | The South Korean Board Of Audit And Inspection

Loss Contingencies [Line Items]

Amounts paid

$ 131

₩ 172

$ 207

₩ 272

$ 76

₩ 100

Amount of taxes not underpaid as ruled by trial court

$ 166

₩ 218

Amount of alleged underpayments not underpaid as ruled by court

$ 41

₩ 54

SAUDI ARABIA | Middle East & Africa

Loss Contingencies [Line Items]

Total PMI net revenues

$ 246

SAUDI ARABIA | Other Litigation | Saudi Arabia Customs General Authority Case

Loss Contingencies [Line Items]

Additional customs duties ordered to be paid

$ 396

$ 396

ر.س 1.5

Pending Litigation | Thailand | Other Litigation | The Department of Special Investigations of the Government of Thailand

Loss Contingencies [Line Items]

Number of defendants | defendant

7

7

Contingencies (Third-Party Guar

Contingencies (Third-Party Guarantees) (Details) $ in Millions, $ in Millions	Jun. 30, 2022	Mar. 31, 2022 CAD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021	Oct. 17, 2020 CAD ($)	Oct. 17, 2020 USD ($)
Canadian Government
Loss Contingencies [Line Items]
Project contribution from government		$ 27	$ 22		$ 173	$ 131
Philip Morris Investment B.V. | Medicago Inc.
Loss Contingencies [Line Items]
Ownership percentage	21%			23%

Income Taxes (Details)

Income Taxes (Details) $ in Millions, Rp in Trillions	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 31, 2021 USD ($)	Oct. 31, 2021 IDR (Rp)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022 USD ($)	Jun. 30, 2021	Dec. 31, 2022
Income Taxes [Line Items]
Effective tax rate (as a percent)			20.30%	22%	20%	21.70%
Other tax expense (benefit)					$ (13)
Amount assessed by taxing authorities	$ 260	Rp 3.8
Pension Plan
Income Taxes [Line Items]
Other tax expense (benefit)					$ (40)
Minimum
Income Taxes [Line Items]
Statute of limitations term					3 years
Maximum
Income Taxes [Line Items]
Statute of limitations term					5 years
Forecast | Minimum
Income Taxes [Line Items]
Effective tax rate (as a percent)							21%
Forecast | Maximum
Income Taxes [Line Items]
Effective tax rate (as a percent)							22%

Indebtedness (Narrative) (Detai

Indebtedness (Narrative) (Details)	Jun. 30, 2022 USD ($) facility	Jun. 23, 2022 USD ($)	May 11, 2022 USD ($)	Jun. 23, 2022 EUR (€)	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Short-term borrowings, carrying value	$ 1,558,000,000				$ 225,000,000
Borrowings under credit facilities	0
Principal amount	$ 6,300,000,000
Number of credit facilities | facility	2
Senior Unsecured Bridge Facility
Debt Instrument [Line Items]
Debt instrument, term			364 days
Principal amount		$ 11,000,000,000	$ 17,000,000,000
Senior Unsecured Term Loan
Debt Instrument [Line Items]
Principal amount		$ 5,800,000,000		€ 5,500,000,000
Senior Unsecured Term Loan | Three year tranche
Debt Instrument [Line Items]
Debt instrument, term		3 years
Principal amount		$ 3,200,000,000		3,000,000,000
Senior Unsecured Term Loan | Five year tranche
Debt Instrument [Line Items]
Principal amount		$ 2,600,000,000		€ 2,500,000,000

Indebtedness (Schedule of Long-

Indebtedness (Schedule of Long-Term Debt) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, including current maturities	$ 26,494	$ 27,581
Less current portion of long-term debt	4,149	2,798
Long-term debt	22,345	24,783
Finance lease, liability	$ 82	71
U.S. Dollar Notes
Debt Instrument [Line Items]
Average interest rate	3.261%
Long-term debt, including current maturities	$ 18,853	19,397
U.S. Dollar Notes | Minimum
Debt Instrument [Line Items]
Interest rate, stated percentage	0.875%
U.S. Dollar Notes | Maximum
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%
Euro Notes | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	1.995%
Long-term debt, including current maturities	$ 7,149	7,687
Euro Notes | Foreign Currency Obligations | Minimum
Debt Instrument [Line Items]
Interest rate, stated percentage	0.125%
Euro Notes | Foreign Currency Obligations | Maximum
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%
Swiss Franc Notes | Foreign Currency Obligations
Debt Instrument [Line Items]
Interest rate, stated percentage	1.625%
Long-term debt, including current maturities	$ 263	273
Other | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	3.496%
Long-term debt, including current maturities	$ 229	$ 224

Indebtedness (Schedule of Fair

Indebtedness (Schedule of Fair Value) (Details) $ in Millions	Jun. 30, 2022 USD ($)
Level 1
Debt Instrument [Line Items]
Fair value of outstanding long-term debt	$ 23,930
Level 2
Debt Instrument [Line Items]
Fair value of outstanding long-term debt	$ 153

Indebtedness (Schedule of Credi

Indebtedness (Schedule of Credit Facilities) (Details) - USD ($)	Jun. 30, 2022	Jun. 23, 2022	May 11, 2022	Jan. 28, 2022
Line of Credit Facility [Line Items]
Committed credit facilities	$ 6,300,000,000
Borrowings under credit facilities	0
Three Hundred Sixty-Four Day Revolving Credit Expiring January 31, 2023
Line of Credit Facility [Line Items]
Committed credit facilities	1,800,000,000
Multi-year Revolving Credit Facility, Expiring February 10, 2026
Line of Credit Facility [Line Items]
Committed credit facilities	2,000,000,000
Multi-year Revolving Credit Facility, Expiring September 29, 2026
Line of Credit Facility [Line Items]
Committed credit facilities	2,500,000,000
Multi-year Revolving Credit Facility, Expiring February 10, 2027
Line of Credit Facility [Line Items]
Committed credit facilities				$ 1,900,000,000
Senior Unsecured Bridge Facility
Line of Credit Facility [Line Items]
Committed credit facilities		$ 11,000,000,000	$ 17,000,000,000
Senior Unsecured Bridge Facility and Senior Unsecured Term Loan
Line of Credit Facility [Line Items]
Borrowings under credit facilities	$ 0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Losses (Components of Accumulated Other Comprehensive Earnings (Losses), Net of Tax) (Details) - USD ($) $ in Millions	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	$ (7,260)	$ (8,203)	$ (8,208)	$ (9,200)	$ (9,574)	$ (10,631)
Accumulated Other Comprehensive Losses
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	(9,043)	$ (9,760)	(9,577)	(10,665)	$ (10,746)	$ (11,181)
Currency translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	(6,558)		(6,701)	(6,586)
Pension and other benefits
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	(2,735)		(2,880)	(4,073)
Derivatives accounted for as hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	$ 250		$ 4	$ (6)

Related Parties - Equity Inve_3

Related Parties - Equity Investments and Other (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Mar. 22, 2019
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 1,036	$ 879
Difference between equity method investment carrying value and book value	902	764
Dividends from unconsolidated subsidiaries	8	176
Equity securities, unrealized gain (loss)	(60)
Equity securities, unrealized gain (loss), net	(47)
Level 1
Schedule of Equity Method Investments [Line Items]
Equity securities, noncurrent	$ 215
IPM India
Schedule of Equity Method Investments [Line Items]
Parent ownership percentage	56.30%
TTI | PMM
Schedule of Equity Method Investments [Line Items]
Noncontrolling ownership percentage	33%
Equity Method Investment Goodwill
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated subsidiaries and equity securities	$ 862	$ 728
Megapolis Group
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 530
Ownership percentage	23%
Cumulative foreign currency translation losses	$ 321
EITA
Schedule of Equity Method Investments [Line Items]
Ownership percentage	49%
STAEM
Schedule of Equity Method Investments [Line Items]
Ownership percentage	25%
STAEM | EITA
Schedule of Equity Method Investments [Line Items]
Ownership percentage	51%
STAEM | Management Et Developpement Des Actifs Et Des Ressources Holding (MADAR Holding)
Schedule of Equity Method Investments [Line Items]
Ownership percentage	49%
RBH
Schedule of Equity Method Investments [Line Items]
Equity securities			$ 3,280

Related Parties - Equity Inve_4

Related Parties - Equity Investments and Other (Balance Sheet and Earnings Activity) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Net revenues	$ 869	$ 835	$ 1,547	$ 1,598
Expenses	17	16	29	33
Receivables	968		968		$ 518
Payables	32		32		25
Megapolis Group
Schedule of Equity Method Investments [Line Items]
Net revenues	606	555	993	1,038
Receivables	725		725		319
Other
Schedule of Equity Method Investments [Line Items]
Net revenues	263	280	554	560
Expenses	17	$ 16	29	$ 33
Receivables	243		243		199
Payables	$ 32		$ 32		$ 25

Sale of Accounts Receivable (De

Sale of Accounts Receivable (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Sale of Accounts Receivable [Abstract]
Servicing liability	$ 0	$ 0
Cumulative trade receivables sold	5,600	5,500
Trade receivables sold and derecognized that remain uncollected	$ 656	$ 701

Product Warranty (Narrative) (D

Product Warranty (Narrative) (Details)	6 Months Ended
	Jun. 30, 2022
Guarantees and Product Warranties [Abstract]
Standard product warranty term	12 months

Product Warranty (Movement in P

Product Warranty (Movement in Product Warranty Obligations) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at beginning of period	$ 113	$ 137
Changes due to:
Warranties issued	67	154
Settlements	(60)	(177)
Currency/Other	2	(1)
Balance at end of period	$ 122	$ 113

Asset Impairment and Exit Cos_3

Asset Impairment and Exit Costs (Narrative) (Details) $ in Millions	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) employee
Restructuring Cost and Reserve [Line Items]
Incurred cost	$ 79		$ 127
Future cash payments for exit costs expected to be paid		$ 47
Contract Termination
Restructuring Cost and Reserve [Line Items]
Incurred cost	0		26		$ 57
Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	$ 79		$ 101
Forecast
Restructuring Cost and Reserve [Line Items]
Future cash payments for exit costs expected to be paid				$ 49
Organizational Design Optimization
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated, inception to date | employee					1,020
Cost incurred to date					$ 308
Organizational Design Optimization | Separation programs
Restructuring Cost and Reserve [Line Items]
Cost incurred to date					300
Organizational Design Optimization | Asset Impairment
Restructuring Cost and Reserve [Line Items]
Cost incurred to date					$ 8

Asset Impairment and Exit Cos_4

Asset Impairment and Exit Costs (Asset Impairment and Exit Costs by Segment) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Incurred cost	$ 79	$ 127
Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	79	101
Contract Termination
Restructuring Cost and Reserve [Line Items]
Incurred cost	0	26	$ 57
European Union | Operating Segments | Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	35	44
Eastern Europe | Operating Segments | Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	7	9
Middle East & Africa | Operating Segments | Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	8	10
South & Southeast Asia | Operating Segments | Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	10	13
East Asia & Australia | Operating Segments | Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	15	20
East Asia & Australia | Operating Segments | Contract Termination
Restructuring Cost and Reserve [Line Items]
Incurred cost	0	26
Americas | Operating Segments | Separation programs
Restructuring Cost and Reserve [Line Items]
Incurred cost	$ 4	$ 5

Asset Impairment and Exit Cos_5

Asset Impairment and Exit Costs (Movement in Exit Cost Liabilities) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Movement in exit cost liabilities
Liability balance, January 1, 2022	$ 142
Charges, net	0
Cash spent	(47)
Currency/other	(5)
Liability balance, June 30, 2022	$ 90

Leases (Details)

Leases (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating lease cost	$ 64	$ 66	$ 126	$ 126
Amortization of right-of-use assets	31	9	47	17
Short-term lease cost	16	15	30	25
Variable lease cost	5	7	11	14
Total lease cost	$ 116	$ 97	$ 214	$ 182